Metabolic acidosis and progression of chronic kidney disease: incidence, pathogenesis, and therapeutic options

array:21 ["pii" => "X2013251412002346" "issn" => "20132514" "doi" => "10.3265/Nefrologia.pre2012.Jul.11515" "estado" => "S300" "fechaPublicacion" => "2012-11-01" "documento" => "article" "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/" "subdocumento" => "fla" "cita" => "Nefrologia (English Version). 2012;32:724-30" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 9283 "formatos" => array:3 [ "EPUB" => 300 "HTML" => 7975 "PDF" => 1008 ] ] "Traduccion" => array:1 [ "es" => array:17 [ "pii" => "X0211699512002349" "issn" => "02116995" "doi" => "10.3265/Nefrologia.pre2012.Jul.11515" "estado" => "S300" "fechaPublicacion" => "2012-11-01" "documento" => "article" "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/" "subdocumento" => "fla" "cita" => "Nefrologia. 2012;32:724-30" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 23955 "formatos" => array:3 [ "EPUB" => 320 "HTML" => 20187 "PDF" => 3448 ] ] "es" => array:10 [ "idiomaDefecto" => true "titulo" => "Acidosis metabólica y avance de la enfermedad renal crónica: incidencia, patogénesis y opciones terapéuticas" "tienePdf" => "es" "tieneTextoCompleto" => 0 "tieneResumen" => array:2 [ 0 => "es" 1 => "en" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "724" "paginaFinal" => "730" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Metabolic acidosis and progression of chronic kidney disease: incidence, pathogenesis, and therapeutic options" ] ] "contieneResumen" => array:2 [ "es" => true "en" => true ] "contienePdf" => array:1 [ "es" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "WPAHS Division of Nephrology and Hypertension. Allegheny General Hospital, WPAHS, Temple University School of Medicine, wpahs division of nephrology and hypertension Allegheny general hospital, wpahs, temple university school of medicine, Luis M. Ortega, luis M Ortega, Swati Arora" "autores" => array:5 [ 0 => array:2 [ "nombre" => "WPAHS" "apellidos" => "Division of Nephrology and Hypertension. Allegheny General Hospital, WPAHS, Temple University School of Medicine" ] 1 => array:2 [ "nombre" => "wpahs" "apellidos" => "division of nephrology and hypertension Allegheny general hospital, wpahs, temple university school of medicine" ] 2 => array:2 [ "nombre" => "Luis M." "apellidos" => "Ortega" ] 3 => array:2 [ "nombre" => "luis M" "apellidos" => "Ortega" ] 4 => array:2 [ "nombre" => "Swati" "apellidos" => "Arora" ] ] ] ] ] "idiomaDefecto" => "es" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "X2013251412002346" "doi" => "10.3265/Nefrologia.pre2012.Jul.11515" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2013251412002346?idApp=UINPBA000064" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699512002349?idApp=UINPBA000064" "url" => "/02116995/0000003200000006/v0_201502091338/X0211699512002349/v0_201502091339/es/main.assets" ] ] "itemSiguiente" => array:17 [ "pii" => "X2013251412002338" "issn" => "20132514" "doi" => "10.3265/Nefrologia.pre2012.Apr.11384" "estado" => "S300" "fechaPublicacion" => "2012-11-01" "documento" => "article" "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/" "subdocumento" => "fla" "cita" => "Nefrologia (English Version). 2012;32:731-42" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 9618 "formatos" => array:3 [ "EPUB" => 291 "HTML" => 8538 "PDF" => 789 ] ] "en" => array:12 [ "idiomaDefecto" => true "titulo" => "Evaluation of spiritual well-being in haemodialysis patients" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "es" 1 => "en" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "731" "paginaFinal" => "742" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Evaluación del bienestar espiritual en pacientes en hemodiálisis" ] ] "contieneResumen" => array:2 [ "es" => true "en" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:8 [ "identificador" => "fig1" "etiqueta" => "Tab. 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "copyright" => "Elsevier España" "figura" => array:1 [ 0 => array:4 [ "imagen" => "11384_16025_43525_en_11384_16025_34517_en_t111384.jpg" "Alto" => 1794 "Ancho" => 1063 "Tamanyo" => 597298 ] ] "descripcion" => array:1 [ "en" => "Abbreviated results for spiritual well-being questions in each scale" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Abilio Reig-Ferrer, M. Dolores Arenas, Rosario Ferrer-Cascales, M. Dolores Fernández-Pascual, Natalia Albaladejo-Blázquez, M. Teresa Gil, Vanesa de la Fuente" "autores" => array:8 [ 0 => null 1 => array:2 [ "nombre" => "Abilio" "apellidos" => "Reig-Ferrer" ] 2 => array:2 [ "nombre" => "M. Dolores" "apellidos" => "Arenas" ] 3 => array:2 [ "nombre" => "Rosario" "apellidos" => "Ferrer-Cascales" ] 4 => array:2 [ "nombre" => "M. Dolores" "apellidos" => "Fernández-Pascual" ] 5 => array:2 [ "nombre" => "Natalia" "apellidos" => "Albaladejo-Blázquez" ] 6 => array:2 [ "nombre" => "M. Teresa" "apellidos" => "Gil" ] 7 => array:2 [ "nombre" => "Vanesa" "apellidos" => "de la Fuente" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "X0211699512002330" "doi" => "10.3265/Nefrologia.pre2012.Apr.11384" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699512002330?idApp=UINPBA000064" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2013251412002338?idApp=UINPBA000064" "url" => "/20132514/0000003200000006/v0_201502091602/X2013251412002338/v0_201502091603/en/main.assets" ] "itemAnterior" => array:17 [ "pii" => "X2013251412002354" "issn" => "20132514" "doi" => "10.3265/Nefrologia.pre2012.Aug.11667" "estado" => "S300" "fechaPublicacion" => "2012-11-01" "documento" => "article" "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/" "subdocumento" => "fla" "cita" => "Nefrologia (English Version). 2012;32:715-23" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 5489 "formatos" => array:3 [ "EPUB" => 266 "HTML" => 4545 "PDF" => 678 ] ] "en" => array:12 [ "idiomaDefecto" => true "titulo" => "Acute kidney injury transcriptomics unveils a relationship between inflammation and ageing" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "es" 1 => "en" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "715" "paginaFinal" => "723" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "La transcriptómica del fracaso renal agudo revela una relación entre inflamación y envejecimiento" ] ] "contieneResumen" => array:2 [ "es" => true "en" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:8 [ "identificador" => "fig1" "etiqueta" => "Fig. 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "copyright" => "Elsevier España" "figura" => array:1 [ 0 => array:4 [ "imagen" => "11667_16025_34732_en_f111667_copia.jpg" "Alto" => 2011 "Ancho" => 1035 "Tamanyo" => 375581 ] ] "descripcion" => array:1 [ "en" => "Gene expression for representative mediators of inflammation and ageing in experimental acute kidney injury (AKI): Transcriptomics results of kidney tissue" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "M. Concepción Izquierdo, María Concepción Izquierdo, Ana B. Sanz, M. Dolores Sánchez-Niño, María Dolores Sánchez-Niño, M. Vanessa Pérez-Gómez, María Vanessa Perez-Gomez, Marta Ruiz-Ortega, Jonay Poveda, Olga Ruiz-Andrés, Olga Ruiz-Andres, Adrián M. Ramos, Juan A. Moreno, Jesús Egido, Alberto Ortiz" "autores" => array:19 [ 0 => array:2 [ "nombre" => "M. Concepción" "apellidos" => "Izquierdo" ] 1 => array:2 [ "nombre" => "María Concepción" "apellidos" => "Izquierdo" ] 2 => array:2 [ "nombre" => "Ana B." "apellidos" => "Sanz" ] 3 => array:2 [ "nombre" => "Ana B." "apellidos" => "Sanz" ] 4 => array:2 [ "nombre" => "M. Dolores" "apellidos" => "Sánchez-Niño" ] 5 => array:2 [ "nombre" => "María Dolores" "apellidos" => "Sánchez-Niño" ] 6 => array:2 [ "nombre" => "M. Vanessa" "apellidos" => "Pérez-Gómez" ] 7 => array:2 [ "nombre" => "María Vanessa" "apellidos" => "Perez-Gomez" ] 8 => array:2 [ "nombre" => "Marta" "apellidos" => "Ruiz-Ortega" ] 9 => array:2 [ "nombre" => "Jonay" "apellidos" => "Poveda" ] 10 => array:2 [ "nombre" => "Jonay" "apellidos" => "Poveda" ] 11 => array:2 [ "nombre" => "Olga" "apellidos" => "Ruiz-Andrés" ] 12 => array:2 [ "nombre" => "Olga" "apellidos" => "Ruiz-Andres" ] 13 => array:2 [ "nombre" => "Adrián M." "apellidos" => "Ramos" ] 14 => array:2 [ "nombre" => "Juan A." "apellidos" => "Moreno" ] 15 => array:2 [ "nombre" => "Jesús" "apellidos" => "Egido" ] 16 => array:2 [ "nombre" => "Jesús" "apellidos" => "Egido" ] 17 => array:2 [ "nombre" => "Alberto" "apellidos" => "Ortiz" ] 18 => array:2 [ "nombre" => "Alberto" "apellidos" => "Ortiz" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "X0211699512002357" "doi" => "10.3265/Nefrologia.pre2012.Aug.11667" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699512002357?idApp=UINPBA000064" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2013251412002354?idApp=UINPBA000064" "url" => "/20132514/0000003200000006/v0_201502091602/X2013251412002354/v0_201502091603/en/main.assets" ] "en" => array:15 [ "idiomaDefecto" => true "titulo" => "Metabolic acidosis and progression of chronic kidney disease: incidence, pathogenesis, and therapeutic options" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "724" "paginaFinal" => "730" ] ] "autores" => array:1 [ 0 => array:3 [ "autoresLista" => "WPAHS Division of Nephrology and Hypertension. Allegheny General Hospital, WPAHS, Temple University School of Medicine, wpahs division of nephrology and hypertension Allegheny general hospital, wpahs, temple university school of medicine, Luis M. Ortega, luis M Ortega, Swati Arora" "autores" => array:5 [ 0 => array:3 [ "nombre" => "WPAHS" "apellidos" => "Division of Nephrology and Hypertension. Allegheny General Hospital, WPAHS, Temple University School of Medicine" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "a" "identificador" => "affa" ] ] ] 1 => array:3 [ "nombre" => "wpahs" "apellidos" => "division of nephrology and hypertension Allegheny general hospital, wpahs, temple university school of medicine" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "b" "identificador" => "affb" ] ] ] 2 => array:4 [ "nombre" => "Luis M." "apellidos" => "Ortega" "email" => array:1 [ 0 => "lortega@wpahs.0rg" ] "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "c" "identificador" => "affc" ] ] ] 3 => array:4 [ "nombre" => "luis M" "apellidos" => "Ortega" "email" => array:1 [ 0 => "lortega@wpahs.0rg" ] "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "d" "identificador" => "affd" ] ] ] 4 => array:3 [ "nombre" => "Swati" "apellidos" => "Arora" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "d" "identificador" => "affd" ] ] ] ] "afiliaciones" => array:4 [ 0 => array:3 [ "entidad" => " Allegheny General Hospital, Pittsburgh, Pennsylvania, USA, " "etiqueta" => "a" "identificador" => "affa" ] 1 => array:3 [ "entidad" => "nephrology and hypertension, allegheny general hospital, pittsburgh, pennsylvania, USA, " "etiqueta" => "b" "identificador" => "affb" ] 2 => array:3 [ "entidad" => "Nephrology and Hypertension, Allegheny General Hospital. WPAHS, Temple University School of Medicine, Pittsburgh, Pennsylvania, USA, " "etiqueta" => "c" "identificador" => "affc" ] 3 => array:3 [ "entidad" => "nephrology and hypertension, Allegheny general hosptial.WPAHS,Temple University School of Medicine, Pittsburgh, Pennsylvania, USA, " "etiqueta" => "d" "identificador" => "affd" ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Acidosis metabólica y avance de la enfermedad renal crónica: incidencia, patogénesis y opciones terapéuticas" ] ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:8 [ "identificador" => "fig1" "etiqueta" => "Tab. 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "copyright" => "Elsevier España" "figura" => array:1 [ 0 => array:4 [ "imagen" => "11515_16025_38600_en_t211515i_copia.jpg" "Alto" => 2005 "Ancho" => 2166 "Tamanyo" => 927107 ] ] "descripcion" => array:1 [ "en" => "Randomized prospective trials in the use of oral bicarbonate in patients with CKD" ] ] ] "textoCompleto" => "INTRODUCTION Metabolic acidosis traditionally defined as a reduction in serum bicarbonate (HCO-3) concentration often associated with a reduction in blood PH, is a common accompaniment of progressive chronic kidney disease (CKD).1 It originates from the reduced capacity of the kidney to synthesize ammonia (NH3) and excrete hydrogen (H+) ions. It can have adverse consequences on protein, muscle and bone metabolism through negative nitrogen balance, increased protein degradation and decreased albumin synthesis, leading to protein energy malnutrition, loss of lean body mass and muscle weakness. It can also affect bone turnover due to its buffer effect compensating for excess acid. This action interferes with vitamin D metabolism, developing osteomalacia and renal osteodytrophy in patients with renal impairment. The mechanisms underlying these effects appear to be complex, involving several different pathways.There is a high incidence of CKD in the general population based on a cross-sectional analysis of the most recent National Health and Nutrition Examination survey (NHANES, from 1988-94 and 1990-2004).2 There is also a correlation between decreased GFR and decrease plasma HCO3- based on the concept of nephron loss and impairment of ammoniagenesis. The question is if metabolic acidosis could be linked to the progression of kidney disease and if so can its correction delay CKD progression.3 Metabolic acidosis may be corrected by oral HCO3 supplementation in CKD and dialysis patients by increasing the HCO3 concentration in dialysis solutions. The absolute benefits of the correction of acidosis are not clearly identified and it is important to review the evidence. This evidence is very limited in pre-end-stage renal disease (ESRD) patients with lack of past or recent randomized control trials (RCT’s). Long term use of oral sodium HCO3 has not been evaluated in patients at risk for sodium overload especially nephrotic syndrome, hypertension or heart failure. Randomized control trials are needed to determine the benefits and risks of HCO3 therapy in preventing progression of CKD in pre-ESRD patients, targeting ideal HCO3 levels to initiate therapy with alkali agents. Di Iorio and colleagues in Italy will be conducting a prospective, multicenter, randomized, controlled trial looking at the correction of metabolic acidosis with oral HCO3 use and its influence in the progression of kidney disease. Randomization will involve 600 patients with CKD stages 3b and 4. Three hundred patients will receive oral sodium HCO3 or citrate.4 EPIDEMIOLOGY Twenty six million Americans have evidence of kidney disease.2 A major determinant of serum HCO3 levels is kidney function. The exact prevalence of metabolic acidosis in patients with CKD is unknown. The Third National Health and Nutrition Examination Survey (NHANES III) analysis found a decrease in plasma HCO3 concentration with estimated glomerular filtration rate (eGFR)5 < than 20mL/min1.73m2. If hypobicarbonatemia caused by metabolic acidosis develops when eGFR is less < than 25% of normal parameters, it would be predicted that 300,000 to 400,000 individuals in the United States might have metabolic acidosis associated with CKD.6 After patients reach age 60 plasma HCO3 concentration is less than normal (12% of the population) and a great number of individuals could develop CKD related metabolic acidosis.7 Eighty percent of patients will manifest hypobicarbonatemia when GFR decreases to less than 20-25% of normal. The metabolic acidosis is mild in degree, with plasma HCO3 concentration between 12mEq/L and 22mEq/L.8 It is rare to have plasma HCO3 values < than 12mEq/L in the absence of increments in dietary acid load or superimposed tubular defect in bicarbonate absorption or generation.9 On the other hand, 10 to 20% with stage 5 CKD, many of whom have diabetes, have a plasma HCO3 concentration close to 23mEq/L.10There could be an inverse correlation between plasma HCO3 concentration and renal function. Widmer et al., evaluated forty one patients retrospectively showing an inverse linear relationship between serum carbon dioxide (CO2) and serum creatinine, with a lower limit for serum CO2 of 11mEq/L at a serum creatinine of 12 mg/dL.11 Data from the NHANES III12 showed that HCO3-levels of 22mEq/L or less were present in 19% of those with eGFR of 15 to 29mL/min/1.73m2. However, the exact prevalence of metabolic acidosis caused solely by CKD remains to be determined. Shah et al.13 studied data from 5,422 patients with different comorbidities (diabetes 21%, HTN 41%) race (African-american 45%, Hispanics 11%) and gender (women 69%). Nine percent had GFR <60ml/min/1.73m2. The lowest quartile of serum HCO3 (≤22 mEq/L) was associated with a 54% increased hazard of progression of kidney disease. After adjusting for potential confounders, the relative hazard ratio (rHR) for progression of kidney disease was 1.54 (95% confidence interval (CI) 1.13-2.09). The study was observational making causality difficult and lack of blood gas analysis could not rule out a respiratory component.Lower serum HCO3- levels are associated with higher all-cause mortality in patients with moderate and advanced CKD. Kovesdy et al.14 evaluated a cohort of 1240 CKD patients (eGFR % 27.5±5.5 to 45.9±19.1). Multivariable-adjusted Cox models showed a U-shaped association with the highest mortality rate with serum HCO3 <22 mmol/L (95%CI) and the lowest mortality with serum bicarbonate of 26-29mmo/L, even after controlling for the confounding effect of nutritional status and inflammation. In 1094 patients,15 from the African American Study of Kidney Disease and Hypertension (AASK) cohort trial study, each 1mmo/L increase in serum HCO3 was associated with reduced risk of death (HR 0.942). One may speculate that protein-energy malnutrition may be related to acidemia and represents a risk factor for poor outcome in renal failure. Despite different clinical scenarios and covariants there is a correlation between worsening renal function and acidosis in the pre-ESRD population. PATHOGENESIS An important function of the kidney is ammoniagnesis. Ammonia is produced in the proximal tubule from glutamine at a high rate. One half of renal NH3 produced leaves via renal veins and the remainder is eliminated in the urine. Patients with CKD present with normal and increased anion-gap metabolic acidosis at early and late stages respectively.9 The mechanism is the impaired renal bicarbonate generation with and without concomitant decreased bicarbonate absorption16 and retention of H+ ions.14 Total ammonium (NH4+) excretion begins to fall when GFR <40 to 50mL/min. Widmer et al.,11 evaluated 41 patients in two different creatinine value groups in an ambulatory setting and 39 patients as controls (Table 1). The renal failure group presented with serum creatinine between 2, 4mg/dL (moderate renal failure subgroup), and 14.4mg/dl (severe renal failure subgroup) respectively. The control group’s serum creatinine ranged from 0.6 to 1.7mg/dl. Serum HCO3 concentration was significantly lower in the moderate and severe groups in comparison with controls. Decrements in CO2 were proportional to the increment in serum creatinine and associated with increments in unmeasured anions, especially in the group with serum creatinine above 4mg/dl. There was no increment of unmeasured anions in the control group. In the other hand, serum Chloride (Cl‾ ) remained unchanged. In a retrospective analysis of 911 patients, Hakim et al.8 noted mixed normal and high anion gap metabolic acidosis, even early in the course of CKD. Dietary differences or abnormalities in gastrointestinal or renal absorption of organic/inorganic anions could account for the lower than expected anion gap in the early stages of renal failure. In fact serum anion gap could be altered by the accumulation of cations (calcium, magnesium or paraproteins).17 Kidney disease associated with more severe tubulointerstitial damage can be accompanied by more severe acidosis in the early stages of renal failure.18Metabolic acidosis develops due to reduced renal mass and inability of the remaining nephrons to excrete the daily acid load through ammoniagenesis. The renal tubular production of NH3 is stimulated by intracellular acidosis. When the systemic acid load is modestly increased, balance is maintained by increase in NH4+ production and excretion. Failure to excrete sufficient NH4+ leads to the net retention of H+ ions and the development of metabolic acidosis. Defects in the ability to secrete NH4+ (proximal tubule) or H+ ions (distal tubule, type A intercalated cells), will translate into tubular acidosis through a pH dependent mechanism. Hyperkalemia, on the other hand, can induce intracellular alkalosis and also competes with potassium in the Na+/K+/2Cl‾ pump located in the thick ascending loop of Henle, diminishing NH4+ formation and preventing excretion of the acid load in the collecting tubules. As stated before single-nephron ammoniagenesis increases as compensation for decreased functioning nephrons.19 Generation of NH3 per nephron is increased but global ammoniagenesis is reduced. Decrease in urine NH4+ excretion is a reflection of decreased proximal renal tubular glutamine uptake and subsequent generation of NH4+ and bicarbonate from α-ketoglutarate.20 Decreased in HCO3 generation from glutamine metabolism leaves the kidney dependent on bicarbonate generation from titratable acid excretion, which is later reduced in later stages of renal failure. Other mechanisms generating metabolic acidosis are: HCO3 wasting due to decrease absorption, with bicarbonate excretion ranging from 4.25% to 17.65% in uremic patients,21 hyporeninemic hypoaldosteronism, and impaired distal renal acidification.22Several factors have been implicated in the progression of renal failure, in particular intraglomerular hypertension.23 Experimental studies in Wistar rats, subject to 5/6 nephrectomies, indicated that metabolic acidosis of CKD could have a role in exacerbating proteinuria, tubulointerstitial injury, and worsening renal failure.24 This data has not been confirmed in other animal studies where the presence of metabolic acidosis delayed the progression of renal failure through prevention of calcium phosphate deposits and increased renal clearance of phosphate and lesser degree of hyperparathyroidism.25The levels of NH3 in vascular and cortical tissues are increased when maximally produced by the renal tubule. The factors which influence the production of NH3- in the kidney are angiotensin II, potassium and aldosterone, whose levels are increased in entities like renovascular hypertension.26 Increased concentration of angiotensin II stimulates ammoniagenesis as well as gluconeogenesis. Potassium depletion and administration of aldosterone may also increase ammoniagenesis.27Four mechanisms have been suggested to explain acidosis induced renal injury:1) Increased in NH3- production28 and activation of the alternative complement pathway with generation of inflammatory mediators as well as alkalinization of the interstitium.29 Increased intrarenal ammonia reacts with the thioester bond in C3 and then induces C3b-like properties (form C3 covertase). Subsequent activation of the alternative pathway results in peritubular deposition of C3 and the membrane attack complex C5b-9 generating chemoattractants of tissue injury.30 On the other hand, there is lack of inflammation in the area of the renal medulla where there is increase NH3 concentration. High urea concentration can dissipate the cytotoxic effect of complement activated my NH3. 2) H+ retention induces endothelin and aldosterone mediated GFR decline even before metabolic acidosis, as demonstrated in 2/3 nephrectomized rat models. Dietary alkali better preserved GFR than both endothelin and aldosterone receptor antagonist.313) Acidosis induced aminoacid degradation through ubiquitin-proteasome with increased renal excretion of NH3.324) Ammoniagenesis may cause renal injury by stimulating the hypertrophy of renal tubular cells.27Renal damage through cell mediated immunity, involving the interaction of cross reacting antigens and antibodies with Tamm-Horsfall glycoproteins in the tubule has been described in patients with renal tubular acidosis with a concomitant urinary tract infection or autoimmune liver disease.33As patient approaches ESRD plasma bicarbonate concentration tend to stabilize between 12-20mEq/L. A small number of this patients have a normal plasma HCO3 concentration and anion gap maybe due to decreased protein intake (decreased sulfate generation) and/or increased fruit intake (citrate).34 TREATMENT Bicarbonate supplementation preserves renal function in experimental CKD. Administration of either citrate or sodium bicarbonate to rats with CKD decreased the severity of tubulointerstitial disease and or the decline in GFR compared with controls receiving sodium chloride.28 The chronic administration of base to Han.S-PRD rats (an animal model of polycystic kidney disease) decreased cyst enlargement and prevented development of interstitial inflammation, chronic fibrosis, and severe renal failure.35 The mechanisms underlying the decline in GFR with metabolic acidosis was examined in rats by Nath et al.28 These investigators provided evidence for a link between acidosis induced stimulation of renal NH3 production by the kidney and progressive tubulointerstital injury, an effect initiated by activation of the complement cascade. Others have suggested that the stimulation of new HCO3 production in the kidney alkalinizes the interstitium encouraging precipitation of calcium in the kidney and renal injury.29 Finally, studies in rats using the remnant kidney model of CKD indicated that the decline in GFR was mediated in part by the actions of excess aldosterone and endothelin, the latter acting via activation of endothelin A receptors.36 The above mentioned studies suggest that metabolic acidosis when present can contribute to progression of CKD, and therefore base (alkali) treatment is warranted. Few studies have examined the effects of amelioration of metabolic acidosis on renal function in humans with CKD, not on renal replacement therapy (only three randomized underpowered controlled trials in ESRD).37 In short term studies, oral sodium HCO3 given to patients with moderate renal failure led to reduced protein catabolism, NH3 production, and tubular damage.38Three recently published studies tried to address this hypothesis (Table 2). Brito-Ashurst et al.,39 randomized 134 patients with creatinine clearance (CrCl) between 15-30ml/min/1.73m2 and serum HCO3 16 to 20mmol/L to either oral sodium HCO3- (600mg three times a week) or no treatment. Average age 54.7 years, mostly diabetics and hypertensives, 50% on an angiotensin converting inhibitor or angiotensin receptor blocker. Baseline blood pressure 124/75.5 in both groups, urinary protein g/24h 1.8-1.7 grams, in the control and HCO3 groups respectively. Two year follow up. Primary end point was rate of CrCl decline (>3 ml/min/1.73m2) and ESRD (CrCl<10 ml/min/1.73m2). Secondary end point was dietary protein intake. Decline in GFR was slower with HCO3 supplementation (CrCl 5.93 vs 1.88ml/min/1.73m2; P<.0001). Fewer patients in the treated group developed ESRD (6.5% vs 33%). There was no mayor difference in the incidence of edema in both groups (30 and 39%). More patients in the supplementation group required hypertensive therapy adjustments (61 vs 48%); this can introduce a bias element since blood pressure elevation could alter glomerular filtration. Bicarbonate supplementation was also associated with increased dietary intake, and decreased protein catabolism and increased lean body mass. Lack of a placebo controlled group, a double blind-design and single center, difficults reproducibility.Phisitkul et al.40 evaluated 59 patients with hypertensive nephropathy and metabolic acidosis in a prospective interventional study. His group randomized 59 patients to sodium (Na+) citrate (30) and no therapy (29). The hypothesis was that oral Na+citrate (1mEq of bicarbonate/kg body weight per day in three divided doses) reduces endothelin production and tubulointerstitial injury in subjects with low GFR. Primary outcome was urine endothelin excretion (ET-1), secondary outcomes were changes in GFR by MDRD (modification in diet in renal disease) formula and by cystatin C derived GFR (GFRcys) (using the CKD-EPI equation). Urine N-acetyl-β-D-glucosaminidase excretion was measured as a marker of tubulointerstitial injury. Baseline GFR was 33.4±8.4 and 33.0±8.5 in both groups. Average systolic blood pressure at 6 months was 132.1±6.3 and 132.4±6.2 in controls and treated patients respectively. At 30 months GFR MDRD and GFRcys declined in both groups but was lower in controls (GFR MDRD ml/min: 24.9±9.7 vs 29.5±8.8 and GFRcys ml/min: 23.0±6.05 vs 27.8±7.4 p-value <.0001). Urine endothelin excretion was lower in the Na+ citrate group than in controls (4.83±1.47 vs 6.92±1.67 ng/g Cr P<.0001 at 30 months). No differences was noted in tubulointerstitial injury, as measured by urine N-acetyl-β-D-glucosaminidase excretion (8.±2.92 vs 9.01±92.07U/g Cr). The study suggested that treatment of metabolic acidosis associated with low GFR due to hypertensive nephropathy ameliorates progressive kidney injury. Limitations were the lack of randomization of Na+ citrate and the small population studied.The same group41 randomized 120 patients to placebo, sodium chloride (NaCl) and sodium bicarbonate (NaHCO3) in a prospective placebo controlled blinded interventional 5 year study. Approximate average GFR was 75.5±6.3ml/min, values that were lower in cysGFR determination. Systolic blood pressure ranged between 152.6±14.7 to 155.3±12.6 ml/min.The GFR rate of change in the NaHCO3 group was lower than the placebo and NaCl groups (-1.47±0.19 ml/min per year, -2.13±0.19 ml/min per year, P=.014, -2.05±0.19 ml/min, P=.029, respectively). GFR was statistically higher in the NaHCO3 group as compared with placebo but not with the NaCl group. By contrast, cysGFR was higher in the NaHCO3 group overall. Of interest, the net acid urinary excretion was lower in the NaHCO3 group in comparison with the placebo and NaCl groups respectively (19.2±5.4, 24.4±5.6, 24.9±5.9) which can explain that the HCO3- treated group had decreased intracellular acid generation, endothelin production and tubulointertitial injury. Limitations were again small groups and alkali effect on kidney creatinine and/or cystatin C handling, illustrating the need for a large scale study.The magnitude of the hypobicarbonatemia present in patients with CKD is variable and, as stated previously, some patients can actually have normal serum HCO3- even in the face of severe renal failure.34 Therefore, the threshold for initiation of base therapy in patients with CKD is important to establish. To address this point Wesson et al.31 examined the effect of alkali on the progression of renal failure in rats with 2/3 nephrectomy who had CKD without significant hypobicarbonatemia. Alkali therapy slowed the decline in GFR, an effect which was related to increased endothelin and aldosterone production. Renal H+ content in these rats was greater than that of Sham-operated controls, observations consistent with tissue acid retention despite the absence of a reduced serum HCO3. As mentioned before41 subsequent studies have corroborated the benefitial effects of sodium bicarbonate in the preservation of GFR. Wesson and collegues42 again examined weather human subjects with stage 2 CKD (GFR 60-90ml/min) with macroalbuminuria but not hypobicarbonatemia had evidence of H+ retention and increased levels of endothelin-1 and aldosterone compared with those with a GFR of >90 ml/min. Levels of these hormones were reduced after 30 days of bicarbonate therapy. They were not able to assess the acid content of the kidney but they indirectly evaluated acid content of tissues by the impact of a HCO3 bolus on serum HCO3 and urinary net acid excretion. These results suggest that tissue acid retention was greater in the CKD 2 group. Certain assumptions were made including similar total body buffering capacity in both groups. However based on their previous studies it is not unreasonable to expect H+ retention in humans as renal function declines even if serum bicarbonate is in normal values. It appears that in both animals and humans as renal function and the ability to eliminate the daily acid load decline, acid retention occurs, which secondarily stimulates endothelin and aldosterone production that contributes to a further decline in GFR.43 The effects of excess endothelin and aldosterone on the kidney might not be the only mechanism by which metabolic acidosis contributes to a decline in GFR. Provision of dietary alkali better preserves GFR than administration of endothelin and aldosterone receptor antagonists.31The trials mentioned above are the only human studies to date in patients with pre-ESRD that showed oral HCO3 as a therapeutic option with minimal side effects, inexpensive and with potential benefit in delaying progression of CKD. CONCLUSION There is a high incidence of CKD in the general population.2 Metabolic acidosis presents early in kidney disease and could be associated with worsening renal function due to perhaps an immunological process, and increased mortality due to protein catabolism. Bicarbonate supplementation represents a therapeutic option easy to apply, economical, and almost devoided of side effects.Alkali therapy could protect against the progression of CKD, especially in early stages with normal serum bicarbonate levels. The mechanisms by which NaHCO3 therapy ameliorates nephropathy progression in unclear but nephrectomized animal models with reduced GFR provided insight to the hypothesis. Animals with reduced nephron mass and low GFR have acid retention compared with those with intact nephron mass despite no differences in serum acid-base parameters.44 Acid retention induces GFR decline mediated by tubulointerstitial injury through endothelin receptors.45The paucity of well designed clinical trials in human subjects is counteracted by the good results obtained in these studies. The optimal therapeutic target as well as its efficacy and safety needs to be determined. The current situation, forces us to use the most practical resources in our armamentarium to try to delay, not to prevent unfortunately, the progression of kidney disease.If confirmed by follow-up studies, implementation of this inexpensive and well tolerated therapy in at risk subjects could yield overall population and health system benefits by delaying the onset of kidney failure with its devastating effects on patient’s wellbeing and health care costs. Conflict of interestThe authors declare that there is no conflict of interest associated with this manuscript.<a href="grande/11515_16025_38600_en_t211515i_copia.jpg" class="elsevierStyleCrossRefs"><img src="11515_16025_38600_en_t211515i_copia.jpg" alt="Randomized prospective trials in the use of oral bicarbonate in patients with CKD"></img></a>Table 2. Randomized prospective trials in the use of oral bicarbonate in patients with CKD<a href="grande/11515_16025_38602_en_t111515i_copia.jpg" class="elsevierStyleCrossRefs"><img src="11515_16025_38602_en_t111515i_copia.jpg" alt="Correlation of serum bicarbonate to changes in serum creatinine"></img></a>Table 1. Correlation of serum bicarbonate to changes in serum creatinine" "pdfFichero" => "P1-E544-S3765-A11515-EN.pdf" "tienePdf" => true "PalabrasClave" => array:2 [ "es" => array:5 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Palabras clave" "identificador" => "xpalclavsec437019" "palabras" => array:1 [ 0 => "Amoniaco" ] ] 1 => array:4 [ "clase" => "keyword" "titulo" => "Palabras clave" "identificador" => "xpalclavsec437021" "palabras" => array:1 [ 0 => "Bicarbonato sódico" ] ] 2 => array:4 [ "clase" => "keyword" "titulo" => "Palabras clave" "identificador" => "xpalclavsec437023" "palabras" => array:1 [ 0 => "ERC" ] ] 3 => array:4 [ "clase" => "keyword" "titulo" => "Palabras clave" "identificador" => "xpalclavsec437025" "palabras" => array:1 [ 0 => "Acidosis metabólica" ] ] 4 => array:4 [ "clase" => "keyword" "titulo" => "Palabras clave" "identificador" => "xpalclavsec437027" "palabras" => array:1 [ 0 => "Mortalidad" ] ] ] "en" => array:5 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec437020" "palabras" => array:1 [ 0 => "Ammonium" ] ] 1 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec437022" "palabras" => array:1 [ 0 => "Sodium bicarbonate" ] ] 2 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec437024" "palabras" => array:1 [ 0 => "CKD" ] ] 3 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec437026" "palabras" => array:1 [ 0 => "Metabolic acidosis" ] ] 4 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec437028" "palabras" => array:1 [ 0 => "Mortality" ] ] ] ] "tieneResumen" => true "resumen" => array:2 [ "es" => array:1 [ "resumen" => "Hay una prevalencia importante de la acidosis metabólica en los pacientes que padecen enfermedad renal crónica, presentándose en niveles tempranos de pérdida de filtrado glomerular. La patogénesis se basa en la falta de síntesis de bicarbonato sérico con la acumulación de ácidos de naturaleza orgánica e inorgánica, ocasionando daño tubulointersticial a través de la retención de amoniaco y el depósito de complemento, aunque esta última hipótesis se ha cuestionado en el pasado. El uso empírico de bicarbonato oral representa una opción terapéutica interesante que ha sido utilizada en estudios clínicos recientes. La disponibilidad de bicarbonato de sodio oral en sus diversas formas representa una opción barata y simple de utilizar para decelerar la progresión de la enfermedad renal, sin mencionar las mejoras en el catabolismo proteico, la osteodistrofia renal y la mortalidad." ] "en" => array:1 [ "resumen" => "In the chronic kidney disease population metabolic acidosis is prevalent presenting already in the early stages of renal dysfunction. The pathogenesis associates the lack of bicarbonate production with the accumulation of organic/inorganic acids and the development of tubulointerstitial damage through ammonium retention and complement deposition. The empiric use of oral sodium bicarbonate represents an interesting therapeutic option that has been documented in a few clinical trials in human subjects. The availability of oral sodium, in its diverse forms, represents an inexpensive and simple way of treating an entity that could hasten the progression of kidney disease, as well as protein catabolism, bone disease and mortality." ] ] "multimedia" => array:2 [ 0 => array:8 [ "identificador" => "fig1" "etiqueta" => "Tab. 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "copyright" => "Elsevier España" "figura" => array:1 [ 0 => array:4 [ "imagen" => "11515_16025_38600_en_t211515i_copia.jpg" "Alto" => 2005 "Ancho" => 2166 "Tamanyo" => 927107 ] ] "descripcion" => array:1 [ "en" => "Randomized prospective trials in the use of oral bicarbonate in patients with CKD" ] ] 1 => array:8 [ "identificador" => "fig2" "etiqueta" => "Tab. 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "copyright" => "Elsevier España" "figura" => array:1 [ 0 => array:4 [ "imagen" => "11515_16025_38602_en_t111515i_copia.jpg" "Alto" => 307 "Ancho" => 2166 "Tamanyo" => 181512 ] ] "descripcion" => array:1 [ "en" => "Correlation of serum bicarbonate to changes in serum creatinine" ] ] ] "bibliografia" => array:2 [ "titulo" => "Bibliography" "seccion" => array:1 [ 0 => array:1 [ "bibliografiaReferencia" => array:45 [ 0 => array:3 [ "identificador" => "bib1" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Kraut JA, Kurtz I. Metabolic acidosis of CKD; diagnosis,clinical characteristics\u{A0}and treatment. Am J Kidney Dis 2005;45:978-93. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15957126" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 1 => array:3 [ "identificador" => "bib2" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, et al. Prevalence of chronic kidney disease in the United States. JAMA 2007;298(17):2038-47. <a href="http://www.ncbi.nlm.nih.gov/pubmed/17986697" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 2 => array:3 [ "identificador" => "bib3" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Kraut JA, Madias NE. Consequences and therapy of the metabolic acidosis of chronic kidney disease. Pediatr Nephrol 2011;26:19-28. <a href="http://www.ncbi.nlm.nih.gov/pubmed/20526632" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 3 => array:3 [ "identificador" => "bib4" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Di Iorio B, Aucella F, Conte G, Cupisti A, Santoro D. A prospective, multicenter, randomized, controlled study: The correction of metabolic acidosis with use of bicarbonate in chronic renal insufficiency (UBI0 study). J Nephrol 2012;25:437-40. <a href="http://www.ncbi.nlm.nih.gov/pubmed/21928233" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 4 => array:3 [ "identificador" => "bib5" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Kraut JA, Kurtz I. Metabolic acidosis of CKD: diagnosis, clinical characteristics, and treatment. Am J Kidney Dis 2005;45:978-93. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15957126" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 5 => array:3 [ "identificador" => "bib6" "etiqueta" => "6" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 2003;41:1-12. <a href="http://www.ncbi.nlm.nih.gov/pubmed/12500213" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 6 => array:3 [ "identificador" => "bib7" "etiqueta" => "7" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Frassetto L, Sebastian A. Age and systemic acid-base equilibrium: Analysis of published data. J Gerontol 1996;51:B91-B99." "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 7 => array:3 [ "identificador" => "bib8" "etiqueta" => "8" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Hakim RM, Lazarus JM. Biochemical parameters in chronic renal failure. Am J Kidney Dis 1988;11:238-47. <a href="http://www.ncbi.nlm.nih.gov/pubmed/3125741" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 8 => array:3 [ "identificador" => "bib9" "etiqueta" => "9" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Relman AS. Renal acidosis and renal excretion of acid in health and disease. Adv Intern Med 1964;12:295-347. <a href="http://www.ncbi.nlm.nih.gov/pubmed/14268281" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 9 => array:3 [ "identificador" => "bib10" "etiqueta" => "10" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Caravaca F, Arrobas M, Pizarro JL, Esparrago JF. Metabolic acidosis in advanced renal failure:differences between diabetic and nondiabetic patients. Am J Kidney Dis 1999;5:892-8." "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 10 => array:3 [ "identificador" => "bib11" "etiqueta" => "11" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Widmer B, Gehardt RE, Harrington JT, Cohen JJ. Serum electrolytes and acid base composition. The influence of graded degrees of chronic renal failure. Arch Int Med 1979;139:1099-102." "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 11 => array:3 [ "identificador" => "bib12" "etiqueta" => "12" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Eustace JA, Astor B, Muntner PM, Ikizler A, Coresh J. Prevalence of acidosis and inflammation and their association with low serum albumin in chronic kidney disease. Kidney Int 2004;65:1031-40. <a href="http://www.ncbi.nlm.nih.gov/pubmed/14871424" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 12 => array:3 [ "identificador" => "bib13" "etiqueta" => "13" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Shah SN, Abramowitz M, Hosletter TH, Melamed ML. Serum bicarbonate levels and the progression of kidney disease:a cohort study. Am J Kidney Dis 2009;54:270-7. <a href="http://www.ncbi.nlm.nih.gov/pubmed/19394734" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 13 => array:3 [ "identificador" => "bib14" "etiqueta" => "14" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Kovesdy CP, Anderson JE, Kalantar-Zadeh K. Association of serum bicarbonate levels with mortality in patients with non-dialysis-dependent CKD. Nephrol Dial Transplant 2009;24:1232-7. <a href="http://www.ncbi.nlm.nih.gov/pubmed/19015169" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 14 => array:3 [ "identificador" => "bib15" "etiqueta" => "15" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Raphael KL, Wei G, Baird BC, Greene T, Beddhu S. Higher serum bicarbonate levels within the normal range are associated with better survival and renal outcomes in African Americans. Kidney Int 2011;79:356-62. <a href="http://www.ncbi.nlm.nih.gov/pubmed/20962743" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 15 => array:3 [ "identificador" => "bib16" "etiqueta" => "16" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Dass PD, Kurtz I. Renal ammonia and bicarbonate production in chronic renal failure. Miner Electrolyte Metab 1990;16:308-14. <a href="http://www.ncbi.nlm.nih.gov/pubmed/1980935" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 16 => array:3 [ "identificador" => "bib17" "etiqueta" => "17" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Kraut JA, Madias NE. Serum anion gap: its uses and limitations in clinical medicine. Clin J Am Soc Nephrol 2007;2:162-74. <a href="http://www.ncbi.nlm.nih.gov/pubmed/17699401" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 17 => array:3 [ "identificador" => "bib18" "etiqueta" => "18" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Sabatini S, Kutzman NA. Enzyme activity in obstructive uropathy: Basis for salt wastage and the acidification defect. Kidney Int 1990;37:79-84. <a href="http://www.ncbi.nlm.nih.gov/pubmed/2153850" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:1 [ "itemHostRev" => array:3 [ "pii" => "S1052305710001850" "estado" => "S300" "issn" => "10523057" ] ] ] ] ] ] ] 18 => array:3 [ "identificador" => "bib19" "etiqueta" => "19" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Maclean AJ, Hayslett JP, Klein-Robbenhaar T, Myketey N. Adaptative change in ammonia excretion in renal insufficiency. Kidney Int 1980;17:595-606. <a href="http://www.ncbi.nlm.nih.gov/pubmed/7401460" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 19 => array:3 [ "identificador" => "bib20" "etiqueta" => "20" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Tizianello A, Ferrari GD, Garibotto G, Gurreri G, Robaudo C. Renal metabolism of amino acids in subjects with normal renal function and in patients with chronic renal insufficiency. J Clin Invest 1980;65:1162-73. <a href="http://www.ncbi.nlm.nih.gov/pubmed/7364943" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 20 => array:3 [ "identificador" => "bib21" "etiqueta" => "21" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Lameire N, Matthys E. Influence of progressive salt restriction on urinary bicarbonate wasting in uremic acidosis. Am J Kidney Dis 1986;8:151-8. <a href="http://www.ncbi.nlm.nih.gov/pubmed/3019127" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 21 => array:3 [ "identificador" => "bib22" "etiqueta" => "22" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Battle DC. Segmental characterization of defects in collecting tubule acidification. Kidney Int 1986;30:546-54. <a href="http://www.ncbi.nlm.nih.gov/pubmed/3784293" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 22 => array:3 [ "identificador" => "bib23" "etiqueta" => "23" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Klahr S, Morrissey J. Progression of chronic renal disease. Am J Kidney Dis 2003;41:S3-S7(Suppl 1). <a href="http://www.ncbi.nlm.nih.gov/pubmed/12776302" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 23 => array:3 [ "identificador" => "bib24" "etiqueta" => "24" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Gadola L, Noboa O, Marquez MN, Rodriguez MJ, Nin N, Boggia J, et al. Calcium citrate ameliorates the progression of chronic renal injury. Kidney Int 2004;65:1224-30. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15086461" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 24 => array:3 [ "identificador" => "bib25" "etiqueta" => "25" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Jara A, Felsenfeld AJ, Bover J, Kleeman CR. Chronic metabolic acidosis in azotemic rats on a high phosphate diet halts the progression of renal disease. Kidney Int 2000;58:1023-32. <a href="http://www.ncbi.nlm.nih.gov/pubmed/10972667" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 25 => array:3 [ "identificador" => "bib26" "etiqueta" => "26" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Agroyannis B, Tzanatos H, Kopelias I, Fourtounas K,\u{A0}Koutsikos D. Renal ammoniagenesis and tubulointerstitial injury in hypertension. Nephrol Dial Transplant 1995;10:2372-3. <a href="http://www.ncbi.nlm.nih.gov/pubmed/8808249" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 26 => array:3 [ "identificador" => "bib27" "etiqueta" => "27" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Chodanican MC, Julin C. Angiotensin II stimulates ammoniagensis in canine renal proximal tubular segments. Am J Physiol 1991;260:F16-F27." "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 27 => array:3 [ "identificador" => "bib28" "etiqueta" => "28" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Nath KA, Hostetter MK, Hostetter TH. Pathophysiology of chronic tubulo-interstitial disease in rats. Interactions of dietary acid load, ammonia, and complement component C3. J Clin Invest 1985;76:667-75. <a href="http://www.ncbi.nlm.nih.gov/pubmed/2993363" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 28 => array:3 [ "identificador" => "bib29" "etiqueta" => "29" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Halperin ML, Eithier JH, Kamel KS. Ammonium excretion in chronic metabolic acidosis: Benefits and risks. Am J Kidney Dis 1989;14:267-71. <a href="http://www.ncbi.nlm.nih.gov/pubmed/2679056" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 29 => array:3 [ "identificador" => "bib30" "etiqueta" => "30" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Nath KA, Hostetter MK, Hostetter TH. Increased ammoniagenesis as a determinant of progressive renal injury. Am J Kidney Dis 1991;17:654-7. <a href="http://www.ncbi.nlm.nih.gov/pubmed/2042643" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 30 => array:3 [ "identificador" => "bib31" "etiqueta" => "31" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Wesson DE, Simoni J. Acid retention during kidney failure induces endothelin and aldosterone production which lead to progressive GFR decline, a situation ameliorated by alkali diet. Kidney Int 2010;78:1128-35. <a href="http://www.ncbi.nlm.nih.gov/pubmed/20861823" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 31 => array:3 [ "identificador" => "bib32" "etiqueta" => "32" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Mitch WE. Influence of metabolic acidosis on nutrition. Am J Kidney Dis 1997;29:xlvi-xlviii." "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 32 => array:3 [ "identificador" => "bib33" "etiqueta" => "33" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Tsantoulas DC, McFarlane IG, Portman B, Eddelston ALWF, Williams R. Cell mediated immunity to human Tamm-Horsfall glycoprotein in autoimmune liver disease with renal tubular acidosis. Br Med J 1974;4:491-4. <a href="http://www.ncbi.nlm.nih.gov/pubmed/4611578" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 33 => array:3 [ "identificador" => "bib34" "etiqueta" => "34" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Wallia R, Greenberg A, Piraino B, Mitro R, Puschett JB. Serum electrolyte patterns in end-stage renal disease. Am J Kidney Dis 1986;8:98. <a href="http://www.ncbi.nlm.nih.gov/pubmed/3090875" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 34 => array:3 [ "identificador" => "bib35" "etiqueta" => "35" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Torres VE, Cowley BDJ, Branden MG, Yoshida I, Gattone VH. Long-term ammonium chloride or sodium bicarbonate treatment in two models of polycystic kidney disease. Exp Nephrol 2001;9:171-80. <a href="http://www.ncbi.nlm.nih.gov/pubmed/11340301" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 35 => array:3 [ "identificador" => "bib36" "etiqueta" => "36" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Wesson DE, Nathan T, Rose T, Simone J, Tran RM. Dietary protein induces endothelin-mediated kidney injury through enhanced intrinsic acid production. Kidney Int 2007;71:210-7. <a href="http://www.ncbi.nlm.nih.gov/pubmed/17164833" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 36 => array:3 [ "identificador" => "bib37" "etiqueta" => "37" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Roderick P, Willis NS, Blakeley S, Jones C, Tomson P. Correction of chronic metabolic acidosis for chronic kidney disease patients. Cochrane Data Base Syst Rev(1):2007,CD001890." "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 37 => array:3 [ "identificador" => "bib38" "etiqueta" => "38" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Rustom R, Grime JS, Costigan M, Maltby P, Hughes A, Taylor W, et al. Oral sodium bicarbonate reduces proximal renal tubular peptide catabolism, ammoniogenesis, and tubular damage in renal patients. Ren Fail 1998;20:371-82. <a href="http://www.ncbi.nlm.nih.gov/pubmed/9574465" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 38 => array:3 [ "identificador" => "bib39" "etiqueta" => "39" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Brito-Ashurst ID, Varagunam M, Raftery MJ, Yaqoop MM. Bicarbonate supplementation slows progression of ckd and improves nutritional status. J Am Soc Nephrol 2009;20:2075-84. <a href="http://www.ncbi.nlm.nih.gov/pubmed/19608703" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 39 => array:3 [ "identificador" => "bib40" "etiqueta" => "40" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Phisitkul S, Khanna A, Simoni J, Broglio K, Sheather S, Rajab MH, et al. Amelioration of metabolic acidosis in patients with low GFR reduced kidney endothelin production and kidney injury, and better preserved GFR. Kidney Int 2010;77:617-23. <a href="http://www.ncbi.nlm.nih.gov/pubmed/20072112" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 40 => array:3 [ "identificador" => "bib41" "etiqueta" => "41" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Mahajan A, Simoni J, Sheather SJ, Broglio KR, Rajab MH, Wesson DE, et al. Daily oral sodium bicarbonate preserves glomerular filtration rate by slowing its decline in early hypertensive nephropathy. Kidney Int 2010;78:303-9. <a href="http://www.ncbi.nlm.nih.gov/pubmed/20445497" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 41 => array:3 [ "identificador" => "bib42" "etiqueta" => "42" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Wesson DE, Simoni J, Broglio K, Sheather SJ. Acid retention accompanies reduced GFR in humans and increase plasma levels of aldosterone and endothelin. Am J Physiol Renal Physiol 2011;300:F830-7. <a href="http://www.ncbi.nlm.nih.gov/pubmed/21270096" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 42 => array:3 [ "identificador" => "bib43" "etiqueta" => "43" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Kraut JA. Effect of metabolic acidosis on progression of chronic kidney disease. Am J Physiol Renal Physiol 2011;300:F828-9. <a href="http://www.ncbi.nlm.nih.gov/pubmed/21307127" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 43 => array:3 [ "identificador" => "bib44" "etiqueta" => "44" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Wesson DE, Simoni J. Increased tissue acid mediates progressive GFR decline in animals with reduced nephron mass. Kidney Int 2009;75:929-35. <a href="http://www.ncbi.nlm.nih.gov/pubmed/19190678" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 44 => array:3 [ "identificador" => "bib45" "etiqueta" => "45" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Phisitkul S, Hacker C, Simoni J, Tran RM, Wesson DE. Dietary protein causes a decline in the glomerular filtration rate of the remnant kidney mediated by metabolic acidosis and endothelin receptors. Kidney Int 2008;73:192-9. <a href="http://www.ncbi.nlm.nih.gov/pubmed/17978813" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/20132514/0000003200000006/v0_201502091602/X2013251412002346/v0_201502091603/en/main.assets" "Apartado" => array:4 [ "identificador" => "35445" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Short Reviews" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/20132514/0000003200000006/v0_201502091602/X2013251412002346/v0_201502091603/en/P1-E544-S3765-A11515-EN.pdf?idApp=UINPBA000064&text.app=https://revistanefrologia.com/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2013251412002346?idApp=UINPBA000064"]

Statistics

Acidosis metabólica y avance de la enfermedad renal crónica: incidencia, patogénesis y opciones terapéuticas

WPAHS Division of Nephrology and Hypertension. Allegheny General Hospital, WPAHS, Temple University School of Medicinea, wpahs division of nephrology and hypertension Allegheny general hospital, wpahs, temple university school of medicineb, Luis M. Ortegac, luis M Ortegad, Swati Arorad

a Allegheny General Hospital, Pittsburgh, Pennsylvania, USA,

b nephrology and hypertension, allegheny general hospital, pittsburgh, pennsylvania, USA,

c Nephrology and Hypertension, Allegheny General Hospital. WPAHS, Temple University School of Medicine, Pittsburgh, Pennsylvania, USA,

d nephrology and hypertension, Allegheny general hosptial.WPAHS,Temple University School of Medicine, Pittsburgh, Pennsylvania, USA,

Read

18330

Times
was read the article

3607

Total PDF

14723

Total HTML

Share statistics

 array:21 [
  "pii" => "X2013251412002346"
  "issn" => "20132514"
  "doi" => "10.3265/Nefrologia.pre2012.Jul.11515"
  "estado" => "S300"
  "fechaPublicacion" => "2012-11-01"
  "documento" => "article"
  "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
  "subdocumento" => "fla"
  "cita" => "Nefrologia &#40;English Version&#41;. 2012;32:724-30"
  "abierto" => array:3 [
    "ES" => true
    "ES2" => true
    "LATM" => true
  ]
  "gratuito" => true
  "lecturas" => array:2 [
    "total" => 9283
    "formatos" => array:3 [
      "EPUB" => 300
      "HTML" => 7975
      "PDF" => 1008
    ]
  ]
  "Traduccion" => array:1 [
    "es" => array:17 [
      "pii" => "X0211699512002349"
      "issn" => "02116995"
      "doi" => "10.3265/Nefrologia.pre2012.Jul.11515"
      "estado" => "S300"
      "fechaPublicacion" => "2012-11-01"
      "documento" => "article"
      "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
      "subdocumento" => "fla"
      "cita" => "Nefrologia. 2012;32:724-30"
      "abierto" => array:3 [
        "ES" => true
        "ES2" => true
        "LATM" => true
      ]
      "gratuito" => true
      "lecturas" => array:2 [
        "total" => 23955
        "formatos" => array:3 [
          "EPUB" => 320
          "HTML" => 20187
          "PDF" => 3448
        ]
      ]
      "es" => array:10 [
        "idiomaDefecto" => true
        "titulo" => "Acidosis metab&#243;lica y avance de la enfermedad renal cr&#243;nica&#58; incidencia&#44; patog&#233;nesis y opciones terap&#233;uticas"
        "tienePdf" => "es"
        "tieneTextoCompleto" => 0
        "tieneResumen" => array:2 [
          0 => "es"
          1 => "en"
        ]
        "paginas" => array:1 [
          0 => array:2 [
            "paginaInicial" => "724"
            "paginaFinal" => "730"
          ]
        ]
        "titulosAlternativos" => array:1 [
          "en" => array:1 [
            "titulo" => "Metabolic acidosis and progression of chronic kidney disease&#58; incidence&#44; pathogenesis&#44; and therapeutic options"
          ]
        ]
        "contieneResumen" => array:2 [
          "es" => true
          "en" => true
        ]
        "contienePdf" => array:1 [
          "es" => true
        ]
        "autores" => array:1 [
          0 => array:2 [
            "autoresLista" => "WPAHS Division of Nephrology and Hypertension&#46; Allegheny General Hospital&#44; WPAHS&#44; Temple University School of Medicine, wpahs division of nephrology and hypertension Allegheny general hospital&#44; wpahs&#44; temple university school of medicine, Luis M&#46; Ortega, luis M Ortega, Swati Arora"
            "autores" => array:5 [
              0 => array:2 [
                "nombre" => "WPAHS"
                "apellidos" => "Division of Nephrology and Hypertension&#46; Allegheny General Hospital&#44; WPAHS&#44; Temple University School of Medicine"
              ]
              1 => array:2 [
                "nombre" => "wpahs"
                "apellidos" => "division of nephrology and hypertension Allegheny general hospital&#44; wpahs&#44; temple university school of medicine"
              ]
              2 => array:2 [
                "nombre" => "Luis M&#46;"
                "apellidos" => "Ortega"
              ]
              3 => array:2 [
                "nombre" => "luis M"
                "apellidos" => "Ortega"
              ]
              4 => array:2 [
                "nombre" => "Swati"
                "apellidos" => "Arora"
              ]
            ]
          ]
        ]
      ]
      "idiomaDefecto" => "es"
      "Traduccion" => array:1 [
        "en" => array:9 [
          "pii" => "X2013251412002346"
          "doi" => "10.3265/Nefrologia.pre2012.Jul.11515"
          "estado" => "S300"
          "subdocumento" => ""
          "abierto" => array:3 [
            "ES" => true
            "ES2" => true
            "LATM" => true
          ]
          "gratuito" => true
          "lecturas" => array:1 [
            "total" => 0
          ]
          "idiomaDefecto" => "en"
          "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2013251412002346?idApp=UINPBA000064"
        ]
      ]
      "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699512002349?idApp=UINPBA000064"
      "url" => "/02116995/0000003200000006/v0_201502091338/X0211699512002349/v0_201502091339/es/main.assets"
    ]
  ]
  "itemSiguiente" => array:17 [
    "pii" => "X2013251412002338"
    "issn" => "20132514"
    "doi" => "10.3265/Nefrologia.pre2012.Apr.11384"
    "estado" => "S300"
    "fechaPublicacion" => "2012-11-01"
    "documento" => "article"
    "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
    "subdocumento" => "fla"
    "cita" => "Nefrologia &#40;English Version&#41;. 2012;32:731-42"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 9618
      "formatos" => array:3 [
        "EPUB" => 291
        "HTML" => 8538
        "PDF" => 789
      ]
    ]
    "en" => array:12 [
      "idiomaDefecto" => true
      "titulo" => "Evaluation of spiritual well-being in haemodialysis patients"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "tieneResumen" => array:2 [
        0 => "es"
        1 => "en"
      ]
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "731"
          "paginaFinal" => "742"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "es" => array:1 [
          "titulo" => "Evaluaci&#243;n del bienestar espiritual en pacientes en hemodi&#225;lisis"
        ]
      ]
      "contieneResumen" => array:2 [
        "es" => true
        "en" => true
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 0
        "multimedia" => array:8 [
          "identificador" => "fig1"
          "etiqueta" => "Tab.  1"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => true
          "mostrarDisplay" => false
          "copyright" => "Elsevier Espa&#241;a"
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "11384_16025_43525_en_11384_16025_34517_en_t111384.jpg"
              "Alto" => 1794
              "Ancho" => 1063
              "Tamanyo" => 597298
            ]
          ]
          "descripcion" => array:1 [
            "en" => "Abbreviated results for spiritual well-being questions in each scale"
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "Abilio Reig-Ferrer, M&#46; Dolores Arenas, Rosario Ferrer-Cascales, M&#46; Dolores Fern&#225;ndez-Pascual, Natalia Albaladejo-Bl&#225;zquez, M&#46; Teresa Gil, Vanesa de la Fuente"
          "autores" => array:8 [
            0 => null
            1 => array:2 [
              "nombre" => "Abilio"
              "apellidos" => "Reig-Ferrer"
            ]
            2 => array:2 [
              "nombre" => "M&#46; Dolores"
              "apellidos" => "Arenas"
            ]
            3 => array:2 [
              "nombre" => "Rosario"
              "apellidos" => "Ferrer-Cascales"
            ]
            4 => array:2 [
              "nombre" => "M&#46; Dolores"
              "apellidos" => "Fern&#225;ndez-Pascual"
            ]
            5 => array:2 [
              "nombre" => "Natalia"
              "apellidos" => "Albaladejo-Bl&#225;zquez"
            ]
            6 => array:2 [
              "nombre" => "M&#46; Teresa"
              "apellidos" => "Gil"
            ]
            7 => array:2 [
              "nombre" => "Vanesa"
              "apellidos" => "de la Fuente"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "Traduccion" => array:1 [
      "es" => array:9 [
        "pii" => "X0211699512002330"
        "doi" => "10.3265/Nefrologia.pre2012.Apr.11384"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => true
          "ES2" => true
          "LATM" => true
        ]
        "gratuito" => true
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "es"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699512002330?idApp=UINPBA000064"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2013251412002338?idApp=UINPBA000064"
    "url" => "/20132514/0000003200000006/v0_201502091602/X2013251412002338/v0_201502091603/en/main.assets"
  ]
  "itemAnterior" => array:17 [
    "pii" => "X2013251412002354"
    "issn" => "20132514"
    "doi" => "10.3265/Nefrologia.pre2012.Aug.11667"
    "estado" => "S300"
    "fechaPublicacion" => "2012-11-01"
    "documento" => "article"
    "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
    "subdocumento" => "fla"
    "cita" => "Nefrologia &#40;English Version&#41;. 2012;32:715-23"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 5489
      "formatos" => array:3 [
        "EPUB" => 266
        "HTML" => 4545
        "PDF" => 678
      ]
    ]
    "en" => array:12 [
      "idiomaDefecto" => true
      "titulo" => "Acute kidney injury transcriptomics unveils a relationship between inflammation and ageing"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "tieneResumen" => array:2 [
        0 => "es"
        1 => "en"
      ]
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "715"
          "paginaFinal" => "723"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "es" => array:1 [
          "titulo" => "La transcript&#243;mica del fracaso renal agudo revela una relaci&#243;n entre inflamaci&#243;n y envejecimiento"
        ]
      ]
      "contieneResumen" => array:2 [
        "es" => true
        "en" => true
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 0
        "multimedia" => array:8 [
          "identificador" => "fig1"
          "etiqueta" => "Fig. 1"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => true
          "mostrarDisplay" => false
          "copyright" => "Elsevier Espa&#241;a"
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "11667_16025_34732_en_f111667_copia.jpg"
              "Alto" => 2011
              "Ancho" => 1035
              "Tamanyo" => 375581
            ]
          ]
          "descripcion" => array:1 [
            "en" => "Gene expression for representative mediators of inflammation and ageing in experimental acute kidney injury &#40;AKI&#41;&#58; Transcriptomics results of kidney tissue"
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "M&#46; Concepci&#243;n Izquierdo, Mar&#237;a Concepci&#243;n Izquierdo, Ana B&#46; Sanz, M&#46; Dolores S&#225;nchez-Ni&#241;o, Mar&#237;a Dolores S&#225;nchez-Ni&#241;o, M&#46; Vanessa P&#233;rez-G&#243;mez, Mar&#237;a Vanessa Perez-Gomez, Marta Ruiz-Ortega, Jonay Poveda, Olga Ruiz-Andr&#233;s, Olga Ruiz-Andres, Adri&#225;n M&#46; Ramos, Juan A&#46; Moreno, Jes&#250;s Egido, Alberto Ortiz"
          "autores" => array:19 [
            0 => array:2 [
              "nombre" => "M&#46; Concepci&#243;n"
              "apellidos" => "Izquierdo"
            ]
            1 => array:2 [
              "nombre" => "Mar&#237;a Concepci&#243;n"
              "apellidos" => "Izquierdo"
            ]
            2 => array:2 [
              "nombre" => "Ana B&#46;"
              "apellidos" => "Sanz"
            ]
            3 => array:2 [
              "nombre" => "Ana B&#46;"
              "apellidos" => "Sanz"
            ]
            4 => array:2 [
              "nombre" => "M&#46; Dolores"
              "apellidos" => "S&#225;nchez-Ni&#241;o"
            ]
            5 => array:2 [
              "nombre" => "Mar&#237;a Dolores"
              "apellidos" => "S&#225;nchez-Ni&#241;o"
            ]
            6 => array:2 [
              "nombre" => "M&#46; Vanessa"
              "apellidos" => "P&#233;rez-G&#243;mez"
            ]
            7 => array:2 [
              "nombre" => "Mar&#237;a Vanessa"
              "apellidos" => "Perez-Gomez"
            ]
            8 => array:2 [
              "nombre" => "Marta"
              "apellidos" => "Ruiz-Ortega"
            ]
            9 => array:2 [
              "nombre" => "Jonay"
              "apellidos" => "Poveda"
            ]
            10 => array:2 [
              "nombre" => "Jonay"
              "apellidos" => "Poveda"
            ]
            11 => array:2 [
              "nombre" => "Olga"
              "apellidos" => "Ruiz-Andr&#233;s"
            ]
            12 => array:2 [
              "nombre" => "Olga"
              "apellidos" => "Ruiz-Andres"
            ]
            13 => array:2 [
              "nombre" => "Adri&#225;n M&#46;"
              "apellidos" => "Ramos"
            ]
            14 => array:2 [
              "nombre" => "Juan A&#46;"
              "apellidos" => "Moreno"
            ]
            15 => array:2 [
              "nombre" => "Jes&#250;s"
              "apellidos" => "Egido"
            ]
            16 => array:2 [
              "nombre" => "Jes&#250;s"
              "apellidos" => "Egido"
            ]
            17 => array:2 [
              "nombre" => "Alberto"
              "apellidos" => "Ortiz"
            ]
            18 => array:2 [
              "nombre" => "Alberto"
              "apellidos" => "Ortiz"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "Traduccion" => array:1 [
      "es" => array:9 [
        "pii" => "X0211699512002357"
        "doi" => "10.3265/Nefrologia.pre2012.Aug.11667"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => true
          "ES2" => true
          "LATM" => true
        ]
        "gratuito" => true
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "es"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699512002357?idApp=UINPBA000064"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2013251412002354?idApp=UINPBA000064"
    "url" => "/20132514/0000003200000006/v0_201502091602/X2013251412002354/v0_201502091603/en/main.assets"
  ]
  "en" => array:15 [
    "idiomaDefecto" => true
    "titulo" => "Metabolic acidosis and progression of chronic kidney disease&#58; incidence&#44; pathogenesis&#44; and therapeutic options"
    "tieneTextoCompleto" => true
    "paginas" => array:1 [
      0 => array:2 [
        "paginaInicial" => "724"
        "paginaFinal" => "730"
      ]
    ]
    "autores" => array:1 [
      0 => array:3 [
        "autoresLista" => "WPAHS Division of Nephrology and Hypertension&#46; Allegheny General Hospital&#44; WPAHS&#44; Temple University School of Medicine, wpahs division of nephrology and hypertension Allegheny general hospital&#44; wpahs&#44; temple university school of medicine, Luis M&#46; Ortega, luis M Ortega, Swati Arora"
        "autores" => array:5 [
          0 => array:3 [
            "nombre" => "WPAHS"
            "apellidos" => "Division of Nephrology and Hypertension&#46; Allegheny General Hospital&#44; WPAHS&#44; Temple University School of Medicine"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "affa"
              ]
            ]
          ]
          1 => array:3 [
            "nombre" => "wpahs"
            "apellidos" => "division of nephrology and hypertension Allegheny general hospital&#44; wpahs&#44; temple university school of medicine"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">b</span>"
                "identificador" => "affb"
              ]
            ]
          ]
          2 => array:4 [
            "nombre" => "Luis M&#46;"
            "apellidos" => "Ortega"
            "email" => array:1 [
              0 => "lortega&#64;wpahs&#46;0rg"
            ]
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">c</span>"
                "identificador" => "affc"
              ]
            ]
          ]
          3 => array:4 [
            "nombre" => "luis M"
            "apellidos" => "Ortega"
            "email" => array:1 [
              0 => "lortega&#64;wpahs&#46;0rg"
            ]
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">d</span>"
                "identificador" => "affd"
              ]
            ]
          ]
          4 => array:3 [
            "nombre" => "Swati"
            "apellidos" => "Arora"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">d</span>"
                "identificador" => "affd"
              ]
            ]
          ]
        ]
        "afiliaciones" => array:4 [
          0 => array:3 [
            "entidad" => " Allegheny General Hospital, Pittsburgh, Pennsylvania, USA, "
            "etiqueta" => "<span class="elsevierStyleSup">a</span>"
            "identificador" => "affa"
          ]
          1 => array:3 [
            "entidad" => "nephrology and hypertension, allegheny general hospital, pittsburgh, pennsylvania, USA, "
            "etiqueta" => "<span class="elsevierStyleSup">b</span>"
            "identificador" => "affb"
          ]
          2 => array:3 [
            "entidad" => "Nephrology and Hypertension, Allegheny General Hospital. WPAHS, Temple University School of Medicine, Pittsburgh, Pennsylvania, USA, "
            "etiqueta" => "<span class="elsevierStyleSup">c</span>"
            "identificador" => "affc"
          ]
          3 => array:3 [
            "entidad" => "nephrology and hypertension, Allegheny general hosptial.WPAHS,Temple University School of Medicine, Pittsburgh, Pennsylvania, USA, "
            "etiqueta" => "<span class="elsevierStyleSup">d</span>"
            "identificador" => "affd"
          ]
        ]
      ]
    ]
    "titulosAlternativos" => array:1 [
      "es" => array:1 [
        "titulo" => "Acidosis metab&#243;lica y avance de la enfermedad renal cr&#243;nica&#58; incidencia&#44; patog&#233;nesis y opciones terap&#233;uticas"
      ]
    ]
    "resumenGrafico" => array:2 [
      "original" => 0
      "multimedia" => array:8 [
        "identificador" => "fig1"
        "etiqueta" => "Tab.  2"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "copyright" => "Elsevier Espa&#241;a"
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "11515_16025_38600_en_t211515i_copia.jpg"
            "Alto" => 2005
            "Ancho" => 2166
            "Tamanyo" => 927107
          ]
        ]
        "descripcion" => array:1 [
          "en" => "Randomized prospective trials in the use of oral bicarbonate in patients with CKD"
        ]
      ]
    ]
    "textoCompleto" => "<p class="elsevierStylePara"><span class="elsevierStyleBold">INTRODUCTION</span></p><p class="elsevierStylePara"><span class="elsevierStyleBold"><span class="elsevierStyleBold">&#160;</span></span></p><p class="elsevierStylePara">Metabolic acidosis traditionally defined as a reduction in serum bicarbonate &#40;HCO<span class="elsevierStyleSup"><span class="elsevierStyleSup">-3</span></span>&#41; concentration often associated with a reduction in blood PH&#44; is a common accompaniment of progressive chronic kidney disease &#40;CKD&#41;<span class="elsevierStyleSup">&#46;<span class="elsevierStyleSup">1</span></span>&#160;It originates from the reduced capacity of the kidney to synthesize ammonia &#40;NH<span class="elsevierStyleInf"><span class="elsevierStyleInf">3</span></span>&#41; and excrete hydrogen &#40;H<span class="elsevierStyleSup"><span class="elsevierStyleSup">&#43;</span></span>&#41; ions&#46; It can have adverse consequences on protein&#44; muscle and bone metabolism through negative nitrogen balance&#44; increased protein degradation and&#160;decreased&#160;albumin synthesis&#44; leading to protein energy malnutrition&#44; loss of lean body mass and muscle weakness&#46; It can also affect bone turnover due to its buffer effect compensating for excess acid&#46; This action interferes with vitamin D metabolism&#44; developing osteomalacia and renal osteodytrophy in patients with renal impairment&#46;&#160;The mechanisms underlying these effects appear to be complex&#44; involving several different pathways&#46;</p><p class="elsevierStylePara">There is a high incidence of CKD in the general population based on a cross-sectional analysis of the most recent National Health and Nutrition Examination survey &#40;NHANES&#44; from 1988-94 and 1990-2004&#41;&#46;<span class="elsevierStyleSup">2</span> There is also a correlation between decreased GFR and decrease plasma HCO<span class="elsevierStyleInf"><span class="elsevierStyleInf">3</span></span><span class="elsevierStyleSup"><span class="elsevierStyleSup">-</span></span>&#160;based on the concept of nephron loss and impairment of ammoniagenesis&#46; The question is if metabolic acidosis could be linked to the progression of kidney disease and if so can its correction delay CKD progression&#46;<span class="elsevierStyleSup">3</span> Metabolic acidosis may be corrected by oral HCO<span class="elsevierStyleSup"><span class="elsevierStyleSup">3</span></span>&#160;supplementation in CKD and dialysis patients by increasing the HCO<span class="elsevierStyleSup"><span class="elsevierStyleSup">3</span></span>&#160;concentration in dialysis solutions&#46; The absolute benefits of the correction of acidosis are not clearly identified and it is important to review the evidence&#46; This evidence is very limited in pre-end-stage renal disease &#40;ESRD&#41; patients with lack of past or recent randomized control trials &#40;RCT&#8217;s&#41;&#46; Long term use of oral sodium HCO<span class="elsevierStyleSup"><span class="elsevierStyleSup">3</span></span>&#160;has not been evaluated in&#160;patients&#160;at risk for sodium overload especially&#160;nephrotic syndrome&#44; hypertension or heart failure&#46; Randomized control trials are needed to determine the benefits and risks of HCO<span class="elsevierStyleSup"><span class="elsevierStyleSup">3</span></span>&#160;therapy in preventing progression of CKD in pre-ESRD patients&#44; targeting ideal HCO<span class="elsevierStyleSup"><span class="elsevierStyleSup">3</span></span><span class="elsevierStyleSup">&#160;</span>levels to initiate therapy with alkali agents&#46;&#160;Di Iorio and colleagues in Italy will be conducting a prospective&#44; multicenter&#44; randomized&#44; controlled trial looking at the correction of metabolic acidosis with oral HCO<span class="elsevierStyleSup"><span class="elsevierStyleSup">3</span></span>&#160;use and its influence in the progression of kidney disease&#46; Randomization will involve 600 patients with CKD stages 3b and 4&#46; Three hundred patients will receive oral sodium HCO<span class="elsevierStyleSup"><span class="elsevierStyleSup">3</span></span>&#160;or citrate&#46;<span class="elsevierStyleSup">4</span></p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara"><span class="elsevierStyleBold">EPIDEMIOLOGY</span></p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara">Twenty six million Americans have evidence of kidney disease&#46;<span class="elsevierStyleSup">2</span> A major determinant of serum HCO<span class="elsevierStyleSup"><span class="elsevierStyleSup">3</span></span>&#160;levels is kidney function&#46; The exact prevalence of metabolic acidosis in patients with CKD is unknown&#46; The Third National Health and Nutrition Examination Survey &#40;NHANES III&#41; analysis found a decrease in plasma HCO<span class="elsevierStyleSup"><span class="elsevierStyleSup">3</span></span>&#160;concentration with estimated glomerular filtration rate &#40;eGFR&#41;<span class="elsevierStyleSup">5</span> &#60; than 20mL&#47;min1&#46;73m<span class="elsevierStyleSup"><span class="elsevierStyleSup">2</span></span>&#46; If hypobicarbonatemia caused by metabolic acidosis develops when eGFR is less &#60; than 25&#37; of normal parameters&#44; it would be predicted that 300&#44;000 to 400&#44;000 individuals in the United States might have metabolic acidosis associated with CKD&#46;<span class="elsevierStyleSup">6</span> After patients reach age 60 plasma HCO<span class="elsevierStyleSup"><span class="elsevierStyleSup">3</span></span>&#160;concentration is less than normal &#40;12&#37; of the population&#41; and a great number of individuals could develop CKD related metabolic acidosis&#46;<span class="elsevierStyleSup">7</span> Eighty percent of patients will manifest hypobicarbonatemia when GFR decreases to less than 20-25&#37; of normal&#46; The metabolic acidosis is mild in degree&#44; with plasma HCO<span class="elsevierStyleSup"><span class="elsevierStyleSup">3</span></span>&#160;concentration between 12mEq&#47;L and 22mEq&#47;L&#46;<span class="elsevierStyleSup">8</span> It is rare to have plasma HCO<span class="elsevierStyleSup"><span class="elsevierStyleSup">3</span></span>&#160;values &#60; than 12mEq&#47;L in the absence of increments in dietary acid load or superimposed tubular defect in bicarbonate absorption or generation&#46;<span class="elsevierStyleSup">9</span> On the other hand&#44; 10 to 20&#37; with stage 5 CKD&#44; many of whom have diabetes&#44; have a plasma HCO<span class="elsevierStyleSup"><span class="elsevierStyleSup">3</span></span>&#160;concentration close to 23mEq&#47;L&#46;<span class="elsevierStyleSup">10</span></p><p class="elsevierStylePara">There could be an inverse correlation between plasma HCO<span class="elsevierStyleSup"><span class="elsevierStyleSup">3</span></span>&#160;concentration and renal function&#46; Widmer et al&#46;&#44; evaluated forty one patients retrospectively showing an inverse linear relationship between serum carbon dioxide &#40;CO<span class="elsevierStyleInf"><span class="elsevierStyleInf">2</span></span>&#41;&#160;and serum creatinine&#44; with a lower limit for serum CO<span class="elsevierStyleInf"><span class="elsevierStyleInf">2</span></span><span class="elsevierStyleInf">&#160;</span>of 11mEq&#47;L at a serum creatinine of 12 mg&#47;dL&#46;<span class="elsevierStyleSup">11</span> Data from the NHANES III<span class="elsevierStyleSup">12</span>&#160;showed that HCO<span class="elsevierStyleInf"><span class="elsevierStyleInf">3</span></span><span class="elsevierStyleSup"><span class="elsevierStyleSup">-</span></span>levels of 22mEq&#47;L or less were present in 19&#37; of those with eGFR of 15 to 29mL&#47;min&#47;1&#46;73m<span class="elsevierStyleSup"><span class="elsevierStyleSup">2</span></span>&#46; However&#44; the exact prevalence of metabolic acidosis caused solely by CKD remains to be determined&#46; Shah et al&#46;<span class="elsevierStyleSup">13</span><span class="elsevierStyleSup">&#160;</span>studied data from 5&#44;422 patients with different comorbidities &#40;diabetes 21&#37;&#44; HTN 41&#37;&#41; race &#40;African-american 45&#37;&#44; Hispanics 11&#37;&#41; and gender &#40;women 69&#37;&#41;&#46; Nine percent had GFR &#60;60ml&#47;min&#47;1&#46;73m<span class="elsevierStyleSup"><span class="elsevierStyleSup">2</span></span>&#46; The lowest quartile of serum HCO<span class="elsevierStyleSup"><span class="elsevierStyleSup">3</span></span>&#160;&#40;&#8804;22 mEq&#47;L&#41; was associated with a 54&#37; increased hazard of progression of kidney disease&#46; After adjusting for potential confounders&#44; the relative hazard ratio &#40;rHR&#41; for progression of kidney disease was 1&#46;54 &#40;95&#37; confidence interval &#40;CI&#41; 1&#46;13-2&#46;09&#41;&#46; The study was observational making causality difficult and lack of blood gas analysis could not rule out a respiratory component&#46;</p><p class="elsevierStylePara">Lower serum HCO<span class="elsevierStyleInf"><span class="elsevierStyleInf">3</span></span><span class="elsevierStyleSup"><span class="elsevierStyleSup">-</span></span>&#160;levels are associated with higher all-cause mortality in patients with moderate and advanced CKD&#46; Kovesdy et al&#46;<span class="elsevierStyleSup">14</span>&#160;evaluated a cohort of 1240 CKD patients &#40;eGFR &#37; 27&#46;5&#177;5&#46;5 to 45&#46;9&#177;19&#46;1&#41;&#46; Multivariable-adjusted Cox models showed a U-shaped association with the highest mortality rate with serum HCO<span class="elsevierStyleSup"><span class="elsevierStyleSup">3</span></span> &#60;22 mmol&#47;L &#40;95&#37;CI&#41; and the lowest mortality with serum bicarbonate of 26-29mmo&#47;L&#44; even after controlling for the confounding effect of nutritional status and inflammation&#46; In 1094 patients&#44;<span class="elsevierStyleSup">15</span> from the African American Study of Kidney Disease and Hypertension &#40;AASK&#41; cohort trial study&#44; each 1mmo&#47;L increase in serum HCO<span class="elsevierStyleSup"><span class="elsevierStyleSup">3</span></span>&#160;was associated with reduced risk of death &#40;HR 0&#46;942&#41;&#46; One may speculate that protein-energy malnutrition may be related to acidemia and represents a risk factor for poor outcome in renal failure&#46; Despite different clinical scenarios and covariants there is a correlation between worsening renal function and acidosis in the pre-ESRD population&#46;</p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara"><span class="elsevierStyleBold">PATHOGENESIS</span></p><p class="elsevierStylePara"><span class="elsevierStyleBold"><span class="elsevierStyleBold">&#160;</span></span></p><p class="elsevierStylePara">An important function of the kidney is ammoniagnesis&#46; Ammonia&#160;is produced in the proximal tubule from glutamine at a high rate&#46; One half of renal NH<span class="elsevierStyleInf"><span class="elsevierStyleInf">3</span></span>&#160;produced leaves via renal veins and the remainder is eliminated in the urine&#46; </p><p class="elsevierStylePara">Patients with CKD present with normal and increased anion-gap metabolic acidosis at early and late stages respectively&#46;<span class="elsevierStyleSup">9</span> The mechanism is the impaired renal bicarbonate generation with and without concomitant decreased bicarbonate absorption<span class="elsevierStyleSup">16</span>&#160;and retention of H<span class="elsevierStyleSup"><span class="elsevierStyleSup">&#43;</span></span>&#160;ions&#46;<span class="elsevierStyleSup">14</span> Total ammonium &#40;NH<span class="elsevierStyleInf"><span class="elsevierStyleInf">4</span></span><span class="elsevierStyleSup"><span class="elsevierStyleSup">&#43;</span></span>&#41; excretion begins to fall when GFR &#60;40 to 50mL&#47;min&#46; Widmer et al&#46;&#44;<span class="elsevierStyleSup">11</span> evaluated 41 patients in two different creatinine value groups in an ambulatory setting&#160;and 39 patients as controls&#160;&#40;Table 1&#41;&#46;&#160;The renal failure group presented with serum creatinine between 2&#44; 4mg&#47;dL &#40;moderate renal failure subgroup&#41;&#44; and 14&#46;4mg&#47;dl &#40;severe renal failure subgroup&#41; respectively&#46; The control group&#8217;s serum creatinine ranged from 0&#46;6 to 1&#46;7mg&#47;dl&#46; Serum HCO<span class="elsevierStyleSup"><span class="elsevierStyleSup">3</span></span>&#160;concentration was significantly lower in the moderate and severe groups in comparison with controls&#46; Decrements in CO2 were proportional to the increment in serum creatinine and associated with increments in unmeasured anions&#44;&#160;especially in the group with serum creatinine above 4mg&#47;dl&#46; There was no increment of unmeasured anions in the control group&#46; In the other hand&#44;&#160;serum Chloride &#40;Cl&#8254; &#41; remained unchanged&#46; In a retrospective analysis of 911 patients&#44; Hakim et al&#46;<span class="elsevierStyleSup">8</span>&#160;noted mixed normal and high anion gap metabolic acidosis&#44; even early in the course of CKD&#46; Dietary differences or abnormalities in gastrointestinal or renal absorption of organic&#47;inorganic anions could account for the lower than expected anion gap in the early stages of renal failure&#46;&#160;In fact serum anion gap could be altered by the accumulation of cations &#40;calcium&#44; magnesium or paraproteins&#41;&#46;<span class="elsevierStyleSup">17</span>&#160;Kidney disease associated with more severe tubulointerstitial damage can be accompanied by more severe acidosis in the early stages of renal failure&#46;<span class="elsevierStyleSup">18</span></p><p class="elsevierStylePara">Metabolic acidosis develops due to reduced renal mass and inability of the remaining nephrons to excrete the daily acid load through ammoniagenesis&#46; The renal tubular production of NH<span class="elsevierStyleInf"><span class="elsevierStyleInf">3</span></span>&#160;is stimulated by intracellular acidosis&#46; When the systemic acid load is modestly increased&#44; balance is maintained by increase in NH<span class="elsevierStyleInf"><span class="elsevierStyleInf">4</span></span><span class="elsevierStyleSup"><span class="elsevierStyleSup">&#43;</span></span>&#160;production and excretion&#46; Failure to excrete sufficient NH<span class="elsevierStyleInf"><span class="elsevierStyleInf">4</span></span><span class="elsevierStyleSup"><span class="elsevierStyleSup">&#43;</span></span>&#160;leads to the net retention of H<span class="elsevierStyleSup"><span class="elsevierStyleSup">&#43;</span></span> ions and the development of metabolic acidosis&#46; Defects in the ability to secrete NH<span class="elsevierStyleInf"><span class="elsevierStyleInf">4</span></span><span class="elsevierStyleSup"><span class="elsevierStyleSup">&#43;</span></span>&#160;&#40;proximal tubule&#41; or H<span class="elsevierStyleSup"><span class="elsevierStyleSup">&#43;</span></span>&#160;ions &#40;distal tubule&#44; type A intercalated cells&#41;&#44; will translate into tubular acidosis through a pH dependent mechanism&#46; Hyperkalemia&#44; on the other hand&#44; can induce intracellular alkalosis and also competes with potassium in the Na<span class="elsevierStyleSup"><span class="elsevierStyleSup">&#43;</span></span>&#47;K<span class="elsevierStyleSup"><span class="elsevierStyleSup">&#43;</span></span>&#47;2Cl<span class="elsevierStyleSup"><span class="elsevierStyleSup">&#8254;</span></span>&#160;pump located in the thick ascending loop of Henle&#44; diminishing NH<span class="elsevierStyleInf"><span class="elsevierStyleInf">4</span></span><span class="elsevierStyleSup"><span class="elsevierStyleSup">&#43;</span></span>&#160;formation and preventing excretion of the acid load in the collecting tubules&#46; As stated before single-nephron ammoniagenesis increases as compensation for decreased functioning nephrons&#46;<span class="elsevierStyleSup">19</span>&#160;Generation of NH<span class="elsevierStyleInf"><span class="elsevierStyleInf">3</span></span>&#160;per nephron is increased but global ammoniagenesis is reduced&#46;&#160;Decrease in urine NH<span class="elsevierStyleInf"><span class="elsevierStyleInf">4</span></span><span class="elsevierStyleSup"><span class="elsevierStyleSup">&#43;</span></span>&#160;excretion is a reflection of decreased proximal renal tubular glutamine uptake and subsequent generation of NH<span class="elsevierStyleInf"><span class="elsevierStyleInf">4</span></span><span class="elsevierStyleSup"><span class="elsevierStyleSup">&#43;</span></span> and bicarbonate from &#945;-ketoglutarate&#46;<span class="elsevierStyleSup">20</span> Decreased in HCO<span class="elsevierStyleSup"><span class="elsevierStyleSup">3</span></span>&#160;generation from glutamine metabolism leaves the kidney dependent on bicarbonate generation from titratable acid excretion&#44; which is later reduced in later stages of renal failure&#46; Other mechanisms generating metabolic acidosis are&#58; HCO<span class="elsevierStyleSup"><span class="elsevierStyleSup">3</span></span>&#160;wasting due to decrease absorption&#44; with bicarbonate excretion ranging from 4&#46;25&#37; to 17&#46;65&#37; in uremic patients&#44;<span class="elsevierStyleSup">21</span> hyporeninemic hypoaldosteronism&#44; and impaired distal renal acidification&#46;<span class="elsevierStyleSup">22</span></p><p class="elsevierStylePara">Several factors have been implicated in the progression of renal failure&#44; in particular intraglomerular hypertension&#46;<span class="elsevierStyleSup">23</span> Experimental studies in Wistar rats&#44; subject to 5&#47;6 nephrectomies&#44; indicated that metabolic acidosis of CKD could have a role in exacerbating proteinuria&#44; tubulointerstitial injury&#44; and worsening renal failure&#46;<span class="elsevierStyleSup">24</span> This data has not been confirmed in other animal studies where the presence of metabolic acidosis delayed the progression of renal failure through prevention of calcium phosphate deposits and increased renal clearance of phosphate and lesser degree of hyperparathyroidism&#46;<span class="elsevierStyleSup">25</span></p><p class="elsevierStylePara">The levels of NH<span class="elsevierStyleInf"><span class="elsevierStyleInf">3</span></span>&#160;in vascular and cortical tissues are increased when maximally produced by the renal tubule&#46; The factors which influence the production of NH<span class="elsevierStyleInf"><span class="elsevierStyleInf">3</span></span><span class="elsevierStyleSup"><span class="elsevierStyleSup">-</span></span>&#160;in the kidney are angiotensin II&#44; potassium and aldosterone&#44; whose levels are increased in entities like renovascular hypertension&#46;<span class="elsevierStyleSup">26</span> Increased concentration of angiotensin II stimulates ammoniagenesis as well as gluconeogenesis&#46; Potassium depletion and administration of aldosterone may also increase ammoniagenesis&#46;<span class="elsevierStyleSup">27</span></p><p class="elsevierStylePara">Four&#160;mechanisms have been suggested to explain acidosis induced renal injury&#58;</p><p class="elsevierStylePara">1&#41; Increased in NH<span class="elsevierStyleInf"><span class="elsevierStyleInf">3</span></span><span class="elsevierStyleSup"><span class="elsevierStyleSup">-</span></span><span class="elsevierStyleBold"><span class="elsevierStyleBold">&#160;</span></span>production<span class="elsevierStyleSup">28</span> and activation of the alternative complement pathway with generation of inflammatory mediators as well as alkalinization of the interstitium&#46;<span class="elsevierStyleSup">29</span> Increased intrarenal ammonia reacts with the thioester bond in C3 and then induces C3b-like properties &#40;form C3 covertase&#41;&#46; Subsequent activation of the alternative pathway results in peritubular deposition of C3 and the membrane attack complex C5b-9 generating chemoattractants of tissue injury&#46;<span class="elsevierStyleSup">30</span>&#160;On the other hand&#44; there is lack of inflammation in the area of the renal medulla where there is increase NH<span class="elsevierStyleInf"><span class="elsevierStyleInf">3</span></span><span class="elsevierStyleSup">&#160;</span>concentration<span class="elsevierStyleSup">&#46;</span>&#160;High urea concentration can dissipate the cytotoxic effect of complement activated my NH<span class="elsevierStyleInf"><span class="elsevierStyleInf">3</span></span>&#46; </p><p class="elsevierStylePara">2&#41; H<span class="elsevierStyleSup"><span class="elsevierStyleSup">&#43;</span></span>&#160;retention induces endothelin and aldosterone mediated GFR decline even before metabolic acidosis&#44; as demonstrated in 2&#47;3 nephrectomized rat models&#46;&#160;Dietary alkali better preserved GFR than both endothelin and aldosterone receptor antagonist&#46;<span class="elsevierStyleSup">31</span></p><p class="elsevierStylePara">3&#41; Acidosis induced aminoacid degradation through ubiquitin-proteasome with increased renal excretion of NH<span class="elsevierStyleInf"><span class="elsevierStyleInf">3</span>&#46;</span><span class="elsevierStyleSup">32</span></p><p class="elsevierStylePara">4&#41; Ammoniagenesis may cause renal injury by stimulating the hypertrophy of renal tubular cells&#46;<span class="elsevierStyleSup">27</span></p><p class="elsevierStylePara">Renal damage through cell mediated immunity&#44; involving the interaction of cross reacting antigens and antibodies with Tamm-Horsfall glycoproteins in the tubule has been described in patients with renal tubular acidosis with a concomitant urinary tract infection or autoimmune liver disease&#46;<span class="elsevierStyleSup">33</span></p><p class="elsevierStylePara">As patient approaches ESRD plasma bicarbonate concentration tend to stabilize between 12-20mEq&#47;L&#46; A small number of this patients have a normal plasma HCO<span class="elsevierStyleSup"><span class="elsevierStyleSup">3</span></span>&#160;concentration and anion gap maybe due to decreased protein intake &#40;decreased sulfate generation&#41; and&#47;or increased fruit intake &#40;citrate&#41;<span class="elsevierStyleSup">&#46;<span class="elsevierStyleSup">34</span></span></p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara"><span class="elsevierStyleBold">TREATMENT</span></p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara">Bicarbonate supplementation preserves renal function in experimental CKD&#46;&#160;Administration&#160;of either citrate or sodium bicarbonate to rats with CKD decreased the severity of tubulointerstitial disease and or the decline in GFR compared with controls receiving sodium chloride<span class="elsevierStyleSup">&#46;<span class="elsevierStyleSup">28&#160;</span></span>The chronic administration of base to Han&#46;S-PRD rats &#40;an animal model of polycystic kidney disease&#41; decreased cyst enlargement&#160;and prevented development of interstitial inflammation&#44; chronic fibrosis&#44; and severe renal failure&#46;<span class="elsevierStyleSup">35</span> The mechanisms underlying the decline in GFR with metabolic acidosis was examined in rats by Nath et al&#46;<span class="elsevierStyleSup">28</span> These investigators provided evidence for a link between acidosis induced stimulation of renal NH<span class="elsevierStyleInf"><span class="elsevierStyleInf">3</span></span>&#160;production by the kidney and progressive tubulointerstital injury&#44; an effect initiated by activation of the complement cascade&#46; Others have suggested that the stimulation of new HCO<span class="elsevierStyleSup"><span class="elsevierStyleSup">3</span></span>&#160;production in the kidney alkalinizes the interstitium encouraging precipitation of calcium in the kidney and renal injury&#46;<span class="elsevierStyleSup">29</span> Finally&#44; studies in rats using the remnant kidney model of CKD indicated that the decline in GFR was mediated in part by the actions of excess aldosterone and endothelin&#44; the latter acting via activation of endothelin A receptors&#46;<span class="elsevierStyleSup">36</span> The above mentioned studies suggest that metabolic acidosis when present can contribute to progression of CKD&#44; and therefore base &#40;alkali&#41; treatment is warranted&#46;&#160;Few studies have examined the effects of amelioration of metabolic acidosis on renal function in humans with CKD&#44; not on renal replacement therapy &#40;only three randomized underpowered controlled trials in ESRD&#41;&#46;<span class="elsevierStyleSup">37</span> In short term studies&#44; oral sodium HCO<span class="elsevierStyleSup"><span class="elsevierStyleSup">3</span></span>&#160;given to patients with moderate renal failure led to reduced protein catabolism&#44; NH<span class="elsevierStyleInf"><span class="elsevierStyleInf">3</span></span>&#160;production&#44; and tubular damage&#46;<span class="elsevierStyleSup">38</span></p><p class="elsevierStylePara">Three recently published studies tried to address this hypothesis&#160;&#40;Table 2&#41;&#46; Brito-Ashurst et al&#46;&#44;<span class="elsevierStyleSup">39</span>&#160;randomized 134 patients with creatinine clearance &#40;CrCl&#41; between 15-30ml&#47;min&#47;1&#46;73m<span class="elsevierStyleSup"><span class="elsevierStyleSup">2</span></span>&#160;and serum HCO<span class="elsevierStyleSup"><span class="elsevierStyleSup">3</span></span>&#160;16 to 20mmol&#47;L to either oral sodium HCO<span class="elsevierStyleInf"><span class="elsevierStyleInf">3</span></span><span class="elsevierStyleSup"><span class="elsevierStyleSup">-</span></span>&#160;&#40;600mg three times a week&#41; or no treatment&#46; Average age 54&#46;7 years&#44; mostly diabetics and hypertensives&#44; 50&#37; on an angiotensin converting inhibitor or angiotensin receptor blocker&#46; Baseline blood pressure 124&#47;75&#46;5 in both groups&#44; urinary protein g&#47;24h 1&#46;8-1&#46;7 grams&#44; in the control and HCO<span class="elsevierStyleSup"><span class="elsevierStyleSup">3</span></span>&#160;groups respectively&#46; Two year follow up&#46; Primary end point was rate of CrCl decline &#40;&#62;3 ml&#47;min&#47;1&#46;73m<span class="elsevierStyleSup"><span class="elsevierStyleSup">2</span></span>&#41; and ESRD &#40;CrCl&#60;10 ml&#47;min&#47;1&#46;73m<span class="elsevierStyleSup"><span class="elsevierStyleSup">2</span></span>&#41;&#46; Secondary end point was dietary protein intake&#46; Decline in GFR was slower with HCO<span class="elsevierStyleSup"><span class="elsevierStyleSup">3</span></span>&#160;supplementation &#40;CrCl 5&#46;93 vs 1&#46;88ml&#47;min&#47;1&#46;73m<span class="elsevierStyleSup"><span class="elsevierStyleSup">2</span></span>&#59; P&#60;&#46;0001&#41;&#46; Fewer patients in the treated group developed ESRD &#40;6&#46;5&#37; vs 33&#37;&#41;&#46; There was no mayor difference in the incidence of edema in both groups &#40;30 and 39&#37;&#41;&#46; More patients in the supplementation group required hypertensive therapy adjustments &#40;61 vs 48&#37;&#41;&#59;&#160;this can introduce a bias element since blood pressure elevation could alter glomerular filtration&#46; Bicarbonate supplementation was also associated with increased dietary intake&#44; and decreased protein catabolism and increased lean body mass&#46; Lack of a placebo controlled group&#44; a double blind-design and single center&#44; difficults reproducibility&#46;</p><p class="elsevierStylePara">Phisitkul et al&#46;<span class="elsevierStyleSup">40</span>&#160;evaluated 59 patients with hypertensive nephropathy and metabolic acidosis in a prospective interventional study&#46; His group randomized 59 patients to sodium &#40;Na<span class="elsevierStyleSup"><span class="elsevierStyleSup">&#43;</span></span>&#41; citrate &#40;30&#41; and no therapy &#40;29&#41;&#46; The hypothesis was that oral Na<span class="elsevierStyleSup"><span class="elsevierStyleSup">&#43;</span></span>citrate &#40;1mEq of bicarbonate&#47;kg body weight per day in three divided doses&#41; reduces endothelin production and tubulointerstitial injury in subjects with low GFR&#46; Primary outcome was urine endothelin excretion &#40;ET-1&#41;&#44; secondary outcomes were changes in GFR by MDRD &#40;modification in diet in renal disease&#41; formula and by cystatin C derived GFR &#40;GFRcys&#41; &#40;using the CKD-EPI equation&#41;&#46; Urine N-acetyl-&#946;-<span class="elsevierStyleInf"><span class="elsevierStyleInf">D</span></span>-glucosaminidase excretion was measured as a marker of tubulointerstitial injury&#46; Baseline GFR was 33&#46;4&#177;8&#46;4 and 33&#46;0&#177;8&#46;5 in both groups&#46; Average systolic blood pressure at 6 months was 132&#46;1&#177;6&#46;3 and 132&#46;4&#177;6&#46;2 in controls and treated patients respectively&#46; At 30 months GFR MDRD and GFRcys declined in both groups but was lower in controls &#40;GFR MDRD ml&#47;min&#58; 24&#46;9&#177;9&#46;7 vs 29&#46;5&#177;8&#46;8 and GFRcys ml&#47;min&#58; 23&#46;0&#177;6&#46;05 vs 27&#46;8&#177;7&#46;4 p-value &#60;&#46;0001&#41;&#46; Urine endothelin excretion was lower in the Na<span class="elsevierStyleSup"><span class="elsevierStyleSup">&#43;</span></span>&#160;citrate group than in controls &#40;4&#46;83&#177;1&#46;47 vs 6&#46;92&#177;1&#46;67 ng&#47;g Cr P&#60;&#46;0001 at 30 months&#41;&#46; No differences was noted in tubulointerstitial injury&#44; as measured by urine N-acetyl-&#946;-<span class="elsevierStyleInf"><span class="elsevierStyleInf">D</span></span>-glucosaminidase excretion &#40;8&#46;&#177;2&#46;92 vs 9&#46;01&#177;92&#46;07U&#47;g Cr&#41;&#46; The study suggested that treatment of metabolic acidosis associated with low GFR due to hypertensive nephropathy ameliorates progressive kidney injury&#46; Limitations were the lack of randomization of Na<span class="elsevierStyleSup"><span class="elsevierStyleSup">&#43;</span></span>&#160;citrate and the small population studied&#46;</p><p class="elsevierStylePara">The same group<span class="elsevierStyleSup">41</span>&#160;randomized 120 patients to placebo&#44; sodium chloride &#40;NaCl&#41; and sodium bicarbonate &#40;NaHCO<span class="elsevierStyleSup"><span class="elsevierStyleSup">3</span></span>&#41; in a prospective placebo controlled blinded interventional 5 year study&#46; Approximate average GFR was 75&#46;5&#177;6&#46;3ml&#47;min&#44; values that were lower in cysGFR determination&#46; Systolic blood pressure ranged between 152&#46;6&#177;14&#46;7 to 155&#46;3&#177;12&#46;6 ml&#47;min&#46;</p><p class="elsevierStylePara">The GFR rate of change in the NaHCO<span class="elsevierStyleInf"><span class="elsevierStyleInf">3</span></span><span class="elsevierStyleInf">&#160;</span>group was lower than the placebo and NaCl groups &#40;-1&#46;47&#177;0&#46;19 ml&#47;min per year&#44; -2&#46;13&#177;0&#46;19 ml&#47;min per year&#44; P&#61;&#46;014&#44; -2&#46;05&#177;0&#46;19 ml&#47;min&#44; P&#61;&#46;029&#44; respectively&#41;&#46; GFR was statistically higher in the NaHCO<span class="elsevierStyleSup"><span class="elsevierStyleSup">3</span></span><span class="elsevierStyleInf"><span class="elsevierStyleInf">&#160;</span></span>group as compared with placebo but not with the NaCl group&#46; By contrast&#44; cysGFR was higher in the NaHCO<span class="elsevierStyleInf"><span class="elsevierStyleInf">3</span></span><span class="elsevierStyleInf">&#160;</span>group overall&#46; Of interest&#44; the net acid urinary excretion was lower in the NaHCO<span class="elsevierStyleInf"><span class="elsevierStyleInf">3</span></span><span class="elsevierStyleInf">&#160;</span>group in comparison with the placebo and NaCl groups respectively &#40;19&#46;2&#177;5&#46;4&#44; 24&#46;4&#177;5&#46;6&#44; 24&#46;9&#177;5&#46;9&#41; which can explain that the HCO<span class="elsevierStyleInf"><span class="elsevierStyleInf">3</span></span><span class="elsevierStyleSup"><span class="elsevierStyleSup">-</span></span> treated group had decreased intracellular acid generation&#44; endothelin production and tubulointertitial injury&#46; Limitations were again small groups and alkali effect on kidney creatinine and&#47;or cystatin C handling&#44; illustrating the need for a large scale study&#46;</p><p class="elsevierStylePara">The magnitude of the hypobicarbonatemia present in patients with CKD is variable and&#44; as stated previously&#44; some patients can actually have normal serum HCO<span class="elsevierStyleInf"><span class="elsevierStyleInf">3</span></span><span class="elsevierStyleSup"><span class="elsevierStyleSup">-</span></span>&#160;even in the face of severe renal failure&#46;<span class="elsevierStyleSup"><span class="elsevierStyleSup">34</span></span> Therefore&#44; the threshold for initiation of base therapy in patients with CKD is important to establish&#46; To address this point Wesson et al&#46;<span class="elsevierStyleSup"><span class="elsevierStyleSup">31</span></span>&#160;examined the effect of alkali on the progression of renal failure in rats with&#160;<span class="elsevierStyleSup">2</span>&#47;<span class="elsevierStyleInf"><span class="elsevierStyleInf">3</span></span>&#160;nephrectomy who had CKD without significant hypobicarbonatemia&#46; Alkali therapy slowed the decline in GFR&#44; an effect which was related to increased endothelin and aldosterone production&#46; Renal H<span class="elsevierStyleSup"><span class="elsevierStyleSup">&#43;</span></span>&#160;content in these rats was greater than that of Sham-operated controls&#44; observations consistent with tissue acid retention despite the absence of a reduced serum HCO<span class="elsevierStyleSup"><span class="elsevierStyleSup">3</span></span>&#46; As mentioned before<span class="elsevierStyleSup">41</span>&#160;subsequent studies have corroborated the benefitial effects of sodium bicarbonate in the preservation of GFR&#46; Wesson and collegues<span class="elsevierStyleSup">42</span>&#160;again examined weather human subjects with stage 2 CKD &#40;GFR 60-90ml&#47;min&#41; with macroalbuminuria but not hypobicarbonatemia had evidence of H<span class="elsevierStyleSup"><span class="elsevierStyleSup">&#43;</span></span>&#160;retention and increased levels of endothelin-1 and aldosterone compared with those with a GFR of &#62;90 ml&#47;min&#46; Levels of these hormones were reduced after 30 days of bicarbonate therapy&#46; They were not able to assess the acid content of the kidney but they indirectly evaluated acid content of tissues by the impact of a HCO<span class="elsevierStyleSup"><span class="elsevierStyleSup">3</span></span>&#160;bolus on serum HCO<span class="elsevierStyleSup"><span class="elsevierStyleSup">3</span></span>&#160;and urinary net acid excretion&#46; These results suggest that tissue acid retention was greater in the CKD 2 group&#46; Certain assumptions were made including similar total body buffering capacity in both groups&#46; However based on their previous studies it is not unreasonable to expect H<span class="elsevierStyleSup"><span class="elsevierStyleSup">&#43;</span></span>&#160;retention in humans as renal function declines even if serum bicarbonate is in normal values&#46; It appears that in both animals and humans as renal function and the ability to eliminate the daily acid load decline&#44; acid retention occurs&#44; which secondarily stimulates endothelin and aldosterone production that contributes to a further decline in GFR&#46;<span class="elsevierStyleSup">43</span> The effects of excess endothelin and aldosterone on the kidney might not be the only mechanism by which metabolic acidosis contributes to a decline in GFR&#46; Provision of dietary alkali better preserves GFR than administration of endothelin and aldosterone receptor antagonists&#46;<span class="elsevierStyleSup">31</span></p><p class="elsevierStylePara">The trials mentioned above are the only human studies to date in patients with pre-ESRD that showed oral HCO<span class="elsevierStyleSup"><span class="elsevierStyleSup">3</span></span>&#160;as a therapeutic option with minimal side effects&#44; inexpensive and with potential benefit in delaying progression of CKD&#46;</p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara"><span class="elsevierStyleBold">CONCLUSION</span></p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara">There is a high incidence of CKD in the general population&#46;<span class="elsevierStyleSup">2</span> Metabolic acidosis presents early in kidney disease and could be associated with worsening renal function due to perhaps an immunological process&#44; and increased mortality due to protein catabolism&#46; Bicarbonate supplementation represents a therapeutic option easy to apply&#44; economical&#44; and almost devoided of side effects&#46;</p><p class="elsevierStylePara">Alkali therapy could protect against the progression of CKD&#44; especially in early stages with normal serum bicarbonate levels&#46; The mechanisms by which NaHCO<span class="elsevierStyleSup"><span class="elsevierStyleSup">3</span></span><span class="elsevierStyleInf">&#160;</span>therapy ameliorates nephropathy progression in unclear but nephrectomized animal models with reduced GFR provided insight to the hypothesis&#46; Animals with reduced nephron mass and low GFR have acid retention compared with those with intact nephron mass despite no differences in serum acid-base parameters&#46;<span class="elsevierStyleSup">44</span> Acid retention induces GFR decline mediated by tubulointerstitial injury through endothelin receptors&#46;<span class="elsevierStyleSup">45</span></p><p class="elsevierStylePara">The paucity of well designed clinical trials in human subjects is counteracted by the good results obtained in these studies&#46; The optimal therapeutic target as well as its efficacy and safety needs to be determined&#46; The current situation&#44; forces us to use the most practical resources in our armamentarium to try to delay&#44; not to prevent unfortunately&#44; the progression of kidney disease&#46;</p><p class="elsevierStylePara">If confirmed by follow-up studies&#44; implementation of this inexpensive and well tolerated therapy in at risk subjects could yield overall population and health system benefits by delaying the onset of kidney failure with its devastating effects on patient&#8217;s wellbeing and health care costs&#46;</p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara"><span class="elsevierStyleBold">Conflict of interest</span></p><p class="elsevierStylePara">The authors declare that there is no conflict of interest associated with this manuscript&#46;</p><p class="elsevierStylePara"><a href="grande&#47;11515&#95;16025&#95;38600&#95;en&#95;t211515i&#95;copia&#46;jpg" class="elsevierStyleCrossRefs"><img src="11515_16025_38600_en_t211515i_copia.jpg" alt="Randomized prospective trials in the use of oral bicarbonate in patients with CKD"></img></a></p><p class="elsevierStylePara">Table 2&#46; Randomized prospective trials in the use of oral bicarbonate in patients with CKD</p><p class="elsevierStylePara"><a href="grande&#47;11515&#95;16025&#95;38602&#95;en&#95;t111515i&#95;copia&#46;jpg" class="elsevierStyleCrossRefs"><img src="11515_16025_38602_en_t111515i_copia.jpg" alt="Correlation of serum bicarbonate to changes in serum creatinine"></img></a></p><p class="elsevierStylePara">Table 1&#46; Correlation of serum bicarbonate to changes in serum creatinine</p>"
    "pdfFichero" => "P1-E544-S3765-A11515-EN.pdf"
    "tienePdf" => true
    "PalabrasClave" => array:2 [
      "es" => array:5 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Palabras clave"
          "identificador" => "xpalclavsec437019"
          "palabras" => array:1 [
            0 => "Amoniaco"
          ]
        ]
        1 => array:4 [
          "clase" => "keyword"
          "titulo" => "Palabras clave"
          "identificador" => "xpalclavsec437021"
          "palabras" => array:1 [
            0 => "Bicarbonato s&#243;dico"
          ]
        ]
        2 => array:4 [
          "clase" => "keyword"
          "titulo" => "Palabras clave"
          "identificador" => "xpalclavsec437023"
          "palabras" => array:1 [
            0 => "ERC"
          ]
        ]
        3 => array:4 [
          "clase" => "keyword"
          "titulo" => "Palabras clave"
          "identificador" => "xpalclavsec437025"
          "palabras" => array:1 [
            0 => "Acidosis metab&#243;lica"
          ]
        ]
        4 => array:4 [
          "clase" => "keyword"
          "titulo" => "Palabras clave"
          "identificador" => "xpalclavsec437027"
          "palabras" => array:1 [
            0 => "Mortalidad"
          ]
        ]
      ]
      "en" => array:5 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Keywords"
          "identificador" => "xpalclavsec437020"
          "palabras" => array:1 [
            0 => "Ammonium"
          ]
        ]
        1 => array:4 [
          "clase" => "keyword"
          "titulo" => "Keywords"
          "identificador" => "xpalclavsec437022"
          "palabras" => array:1 [
            0 => "Sodium bicarbonate"
          ]
        ]
        2 => array:4 [
          "clase" => "keyword"
          "titulo" => "Keywords"
          "identificador" => "xpalclavsec437024"
          "palabras" => array:1 [
            0 => "CKD"
          ]
        ]
        3 => array:4 [
          "clase" => "keyword"
          "titulo" => "Keywords"
          "identificador" => "xpalclavsec437026"
          "palabras" => array:1 [
            0 => "Metabolic acidosis"
          ]
        ]
        4 => array:4 [
          "clase" => "keyword"
          "titulo" => "Keywords"
          "identificador" => "xpalclavsec437028"
          "palabras" => array:1 [
            0 => "Mortality"
          ]
        ]
      ]
    ]
    "tieneResumen" => true
    "resumen" => array:2 [
      "es" => array:1 [
        "resumen" => "<p class="elsevierStylePara">Hay una prevalencia importante de la acidosis metab&#243;lica en los pacientes que padecen enfermedad renal cr&#243;nica&#44; present&#225;ndose en niveles tempranos de p&#233;rdida de filtrado glomerular&#46; La patog&#233;nesis se basa en la falta de s&#237;ntesis de bicarbonato s&#233;rico con la acumulaci&#243;n de &#225;cidos de naturaleza org&#225;nica e inorg&#225;nica&#44; ocasionando da&#241;o tubulointersticial a trav&#233;s de la retenci&#243;n de amoniaco y el dep&#243;sito de complemento&#44; aunque esta &#250;ltima hip&#243;tesis se ha cuestionado en el pasado&#46; El uso emp&#237;rico de bicarbonato oral representa una opci&#243;n terap&#233;utica interesante&#160;que ha sido utilizada en estudios cl&#237;nicos recientes&#46; La disponibilidad de bicarbonato de sodio oral en sus diversas formas representa una opci&#243;n barata y simple de utilizar para decelerar la progresi&#243;n de la enfermedad renal&#44; sin mencionar las mejoras en el catabolismo proteico&#44; la osteodistrofia renal y la mortalidad&#46;</p>"
      ]
      "en" => array:1 [
        "resumen" => "<p class="elsevierStylePara">In the chronic kidney disease population metabolic acidosis is prevalent presenting already in the early stages of renal dysfunction&#46; The pathogenesis associates the lack of bicarbonate production with the accumulation of organic&#47;inorganic acids and the development of tubulointerstitial damage through ammonium retention and complement deposition&#46; The empiric use of oral sodium bicarbonate represents an interesting therapeutic option that has been documented in a few clinical trials in human subjects&#46; The availability of oral sodium&#44; in its diverse forms&#44; represents an inexpensive and simple way of treating an entity that could hasten the progression of kidney disease&#44; as well as protein catabolism&#44; bone disease and mortality&#46;</p>"
      ]
    ]
    "multimedia" => array:2 [
      0 => array:8 [
        "identificador" => "fig1"
        "etiqueta" => "Tab.  2"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "copyright" => "Elsevier Espa&#241;a"
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "11515_16025_38600_en_t211515i_copia.jpg"
            "Alto" => 2005
            "Ancho" => 2166
            "Tamanyo" => 927107
          ]
        ]
        "descripcion" => array:1 [
          "en" => "Randomized prospective trials in the use of oral bicarbonate in patients with CKD"
        ]
      ]
      1 => array:8 [
        "identificador" => "fig2"
        "etiqueta" => "Tab.  1"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "copyright" => "Elsevier Espa&#241;a"
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "11515_16025_38602_en_t111515i_copia.jpg"
            "Alto" => 307
            "Ancho" => 2166
            "Tamanyo" => 181512
          ]
        ]
        "descripcion" => array:1 [
          "en" => "Correlation of serum bicarbonate to changes in serum creatinine"
        ]
      ]
    ]
    "bibliografia" => array:2 [
      "titulo" => "Bibliography"
      "seccion" => array:1 [
        0 => array:1 [
          "bibliografiaReferencia" => array:45 [
            0 => array:3 [
              "identificador" => "bib1"
              "etiqueta" => "1"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Kraut JA, Kurtz I. Metabolic acidosis of CKD; diagnosis,clinical characteristics\u{A0}and treatment. Am J Kidney Dis 2005;45:978-93. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15957126" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            1 => array:3 [
              "identificador" => "bib2"
              "etiqueta" => "2"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, et al. Prevalence of chronic kidney disease in the United States. JAMA 2007;298(17):2038-47. <a href="http://www.ncbi.nlm.nih.gov/pubmed/17986697" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            2 => array:3 [
              "identificador" => "bib3"
              "etiqueta" => "3"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Kraut JA, Madias NE. Consequences and therapy of the metabolic acidosis of chronic kidney disease. Pediatr Nephrol 2011;26:19-28. <a href="http://www.ncbi.nlm.nih.gov/pubmed/20526632" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            3 => array:3 [
              "identificador" => "bib4"
              "etiqueta" => "4"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Di Iorio B, Aucella F, Conte G, Cupisti A, Santoro D. A prospective, multicenter, randomized, controlled study: The correction of metabolic acidosis with use of bicarbonate in chronic renal insufficiency (UBI0 study). J Nephrol 2012;25:437-40. <a href="http://www.ncbi.nlm.nih.gov/pubmed/21928233" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            4 => array:3 [
              "identificador" => "bib5"
              "etiqueta" => "5"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Kraut JA, Kurtz I. Metabolic acidosis of CKD: diagnosis, clinical characteristics, and treatment. Am J Kidney Dis 2005;45:978-93. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15957126" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            5 => array:3 [
              "identificador" => "bib6"
              "etiqueta" => "6"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 2003;41:1-12. <a href="http://www.ncbi.nlm.nih.gov/pubmed/12500213" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            6 => array:3 [
              "identificador" => "bib7"
              "etiqueta" => "7"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Frassetto L, Sebastian A. Age and systemic acid-base equilibrium: Analysis of published data. J Gerontol 1996;51:B91-B99."
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            7 => array:3 [
              "identificador" => "bib8"
              "etiqueta" => "8"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Hakim RM, Lazarus JM. Biochemical parameters in chronic renal failure. Am J Kidney Dis 1988;11:238-47. <a href="http://www.ncbi.nlm.nih.gov/pubmed/3125741" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            8 => array:3 [
              "identificador" => "bib9"
              "etiqueta" => "9"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Relman AS. Renal acidosis and renal excretion of acid in health and disease. Adv Intern Med 1964;12:295-347. <a href="http://www.ncbi.nlm.nih.gov/pubmed/14268281" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            9 => array:3 [
              "identificador" => "bib10"
              "etiqueta" => "10"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Caravaca F, Arrobas M, Pizarro JL, Esparrago JF. Metabolic acidosis in advanced renal failure:differences between diabetic and nondiabetic patients. Am J Kidney Dis 1999;5:892-8."
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            10 => array:3 [
              "identificador" => "bib11"
              "etiqueta" => "11"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Widmer B, Gehardt RE, Harrington JT, Cohen JJ. Serum electrolytes and acid base composition. The influence of graded degrees of chronic renal failure. Arch Int Med 1979;139:1099-102."
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            11 => array:3 [
              "identificador" => "bib12"
              "etiqueta" => "12"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Eustace JA, Astor B, Muntner PM, Ikizler A, Coresh J. Prevalence of acidosis and inflammation and their association with low serum albumin in chronic kidney disease. Kidney Int 2004;65:1031-40. <a href="http://www.ncbi.nlm.nih.gov/pubmed/14871424" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            12 => array:3 [
              "identificador" => "bib13"
              "etiqueta" => "13"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Shah SN, Abramowitz M, Hosletter TH, Melamed ML. Serum bicarbonate levels and the progression of kidney disease:a cohort study. Am J Kidney Dis 2009;54:270-7. <a href="http://www.ncbi.nlm.nih.gov/pubmed/19394734" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            13 => array:3 [
              "identificador" => "bib14"
              "etiqueta" => "14"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Kovesdy CP, Anderson JE, Kalantar-Zadeh K. Association of serum bicarbonate levels with mortality in patients with non-dialysis-dependent CKD. Nephrol Dial Transplant 2009;24:1232-7. <a href="http://www.ncbi.nlm.nih.gov/pubmed/19015169" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            14 => array:3 [
              "identificador" => "bib15"
              "etiqueta" => "15"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Raphael KL, Wei G, Baird BC, Greene T, Beddhu S. Higher serum bicarbonate levels within the normal range are associated with better survival and renal outcomes in African Americans. Kidney Int 2011;79:356-62. <a href="http://www.ncbi.nlm.nih.gov/pubmed/20962743" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            15 => array:3 [
              "identificador" => "bib16"
              "etiqueta" => "16"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Dass PD, Kurtz I. Renal ammonia and bicarbonate production in chronic renal failure. Miner Electrolyte Metab 1990;16:308-14. <a href="http://www.ncbi.nlm.nih.gov/pubmed/1980935" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            16 => array:3 [
              "identificador" => "bib17"
              "etiqueta" => "17"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Kraut JA, Madias NE. Serum anion gap: its uses and limitations in clinical medicine. Clin J Am Soc Nephrol 2007;2:162-74. <a href="http://www.ncbi.nlm.nih.gov/pubmed/17699401" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            17 => array:3 [
              "identificador" => "bib18"
              "etiqueta" => "18"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Sabatini S, Kutzman NA. Enzyme activity in obstructive uropathy: Basis for salt wastage and the acidification defect. Kidney Int 1990;37:79-84. <a href="http://www.ncbi.nlm.nih.gov/pubmed/2153850" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:1 [
                        "itemHostRev" => array:3 [
                          "pii" => "S1052305710001850"
                          "estado" => "S300"
                          "issn" => "10523057"
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            18 => array:3 [
              "identificador" => "bib19"
              "etiqueta" => "19"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Maclean AJ, Hayslett JP, Klein-Robbenhaar T, Myketey N. Adaptative change in ammonia excretion in renal insufficiency. Kidney Int 1980;17:595-606. <a href="http://www.ncbi.nlm.nih.gov/pubmed/7401460" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            19 => array:3 [
              "identificador" => "bib20"
              "etiqueta" => "20"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Tizianello A, Ferrari GD, Garibotto G, Gurreri G, Robaudo C. Renal metabolism of amino acids in subjects with normal renal function and in patients with chronic renal insufficiency. J Clin Invest 1980;65:1162-73. <a href="http://www.ncbi.nlm.nih.gov/pubmed/7364943" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            20 => array:3 [
              "identificador" => "bib21"
              "etiqueta" => "21"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Lameire N, Matthys E. Influence of progressive salt restriction on urinary bicarbonate wasting in uremic acidosis. Am J Kidney Dis 1986;8:151-8. <a href="http://www.ncbi.nlm.nih.gov/pubmed/3019127" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            21 => array:3 [
              "identificador" => "bib22"
              "etiqueta" => "22"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Battle DC. Segmental characterization of defects in collecting tubule acidification. Kidney Int 1986;30:546-54. <a href="http://www.ncbi.nlm.nih.gov/pubmed/3784293" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            22 => array:3 [
              "identificador" => "bib23"
              "etiqueta" => "23"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Klahr S, Morrissey J. Progression of chronic renal disease. Am J Kidney Dis 2003;41:S3-S7(Suppl 1). <a href="http://www.ncbi.nlm.nih.gov/pubmed/12776302" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            23 => array:3 [
              "identificador" => "bib24"
              "etiqueta" => "24"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Gadola L, Noboa O, Marquez MN, Rodriguez MJ, Nin N, Boggia J, et al. Calcium citrate ameliorates the progression of chronic renal injury. Kidney Int 2004;65:1224-30. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15086461" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            24 => array:3 [
              "identificador" => "bib25"
              "etiqueta" => "25"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Jara A, Felsenfeld AJ, Bover J, Kleeman CR. Chronic metabolic acidosis in azotemic rats on a high phosphate diet halts the progression of renal disease. Kidney Int 2000;58:1023-32. <a href="http://www.ncbi.nlm.nih.gov/pubmed/10972667" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            25 => array:3 [
              "identificador" => "bib26"
              "etiqueta" => "26"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Agroyannis B, Tzanatos H, Kopelias I, Fourtounas K,\u{A0}Koutsikos D. Renal ammoniagenesis and tubulointerstitial injury in hypertension. Nephrol Dial Transplant 1995;10:2372-3. <a href="http://www.ncbi.nlm.nih.gov/pubmed/8808249" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            26 => array:3 [
              "identificador" => "bib27"
              "etiqueta" => "27"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Chodanican MC, Julin C. Angiotensin II stimulates ammoniagensis in canine renal proximal tubular segments. Am J Physiol 1991;260:F16-F27."
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            27 => array:3 [
              "identificador" => "bib28"
              "etiqueta" => "28"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Nath KA, Hostetter MK, Hostetter TH. Pathophysiology of chronic tubulo-interstitial disease in rats. Interactions of dietary acid load, ammonia, and complement component C3. J Clin Invest 1985;76:667-75. <a href="http://www.ncbi.nlm.nih.gov/pubmed/2993363" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            28 => array:3 [
              "identificador" => "bib29"
              "etiqueta" => "29"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Halperin ML, Eithier JH, Kamel KS. Ammonium excretion in chronic metabolic acidosis: Benefits and risks. Am J Kidney Dis 1989;14:267-71. <a href="http://www.ncbi.nlm.nih.gov/pubmed/2679056" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            29 => array:3 [
              "identificador" => "bib30"
              "etiqueta" => "30"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Nath KA, Hostetter MK, Hostetter TH. Increased ammoniagenesis as a determinant of progressive renal injury. Am J Kidney Dis 1991;17:654-7. <a href="http://www.ncbi.nlm.nih.gov/pubmed/2042643" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            30 => array:3 [
              "identificador" => "bib31"
              "etiqueta" => "31"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Wesson DE, Simoni J. Acid retention during kidney failure induces endothelin and aldosterone production which lead to progressive GFR decline, a situation ameliorated by alkali diet. Kidney Int 2010;78:1128-35. <a href="http://www.ncbi.nlm.nih.gov/pubmed/20861823" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            31 => array:3 [
              "identificador" => "bib32"
              "etiqueta" => "32"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Mitch WE. Influence of metabolic acidosis on nutrition. Am J Kidney Dis 1997;29:xlvi-xlviii."
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            32 => array:3 [
              "identificador" => "bib33"
              "etiqueta" => "33"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Tsantoulas DC, McFarlane IG, Portman B, Eddelston ALWF, Williams R. Cell mediated immunity to human Tamm-Horsfall glycoprotein in autoimmune liver disease with renal tubular acidosis. Br Med J 1974;4:491-4. <a href="http://www.ncbi.nlm.nih.gov/pubmed/4611578" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            33 => array:3 [
              "identificador" => "bib34"
              "etiqueta" => "34"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Wallia R, Greenberg A, Piraino B, Mitro R, Puschett JB. Serum electrolyte patterns in end-stage renal disease. Am J Kidney Dis 1986;8:98. <a href="http://www.ncbi.nlm.nih.gov/pubmed/3090875" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            34 => array:3 [
              "identificador" => "bib35"
              "etiqueta" => "35"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Torres VE, Cowley BDJ, Branden MG, Yoshida I, Gattone VH. Long-term ammonium chloride or sodium bicarbonate treatment in two models of polycystic kidney disease. Exp Nephrol 2001;9:171-80. <a href="http://www.ncbi.nlm.nih.gov/pubmed/11340301" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            35 => array:3 [
              "identificador" => "bib36"
              "etiqueta" => "36"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Wesson DE, Nathan T, Rose T, Simone J, Tran RM. Dietary protein induces endothelin-mediated kidney injury through enhanced intrinsic acid production. Kidney Int 2007;71:210-7. <a href="http://www.ncbi.nlm.nih.gov/pubmed/17164833" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            36 => array:3 [
              "identificador" => "bib37"
              "etiqueta" => "37"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Roderick P, Willis NS, Blakeley S, Jones C, Tomson P. Correction of chronic metabolic acidosis for chronic kidney disease patients. Cochrane Data Base Syst Rev(1):2007,CD001890."
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            37 => array:3 [
              "identificador" => "bib38"
              "etiqueta" => "38"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Rustom R, Grime JS, Costigan M, Maltby P, Hughes A, Taylor W, et al. Oral sodium bicarbonate reduces proximal renal tubular peptide catabolism, ammoniogenesis, and tubular damage in renal patients. Ren Fail 1998;20:371-82. <a href="http://www.ncbi.nlm.nih.gov/pubmed/9574465" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            38 => array:3 [
              "identificador" => "bib39"
              "etiqueta" => "39"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Brito-Ashurst ID, Varagunam M, Raftery MJ, Yaqoop MM. Bicarbonate supplementation slows progression of ckd and improves nutritional status. J Am Soc Nephrol 2009;20:2075-84. <a href="http://www.ncbi.nlm.nih.gov/pubmed/19608703" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            39 => array:3 [
              "identificador" => "bib40"
              "etiqueta" => "40"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Phisitkul S, Khanna A, Simoni J, Broglio K, Sheather S, Rajab MH, et al. Amelioration of metabolic acidosis in patients with low GFR reduced kidney endothelin production and kidney injury, and better preserved GFR. Kidney Int 2010;77:617-23. <a href="http://www.ncbi.nlm.nih.gov/pubmed/20072112" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            40 => array:3 [
              "identificador" => "bib41"
              "etiqueta" => "41"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Mahajan A, Simoni J, Sheather SJ, Broglio KR, Rajab MH, Wesson DE, et al. Daily oral sodium bicarbonate preserves glomerular filtration rate by slowing its decline in early hypertensive nephropathy. Kidney Int 2010;78:303-9. <a href="http://www.ncbi.nlm.nih.gov/pubmed/20445497" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            41 => array:3 [
              "identificador" => "bib42"
              "etiqueta" => "42"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Wesson DE, Simoni J, Broglio K, Sheather SJ. Acid retention accompanies reduced GFR in humans and increase plasma levels of aldosterone and endothelin. Am J Physiol Renal Physiol 2011;300:F830-7. <a href="http://www.ncbi.nlm.nih.gov/pubmed/21270096" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            42 => array:3 [
              "identificador" => "bib43"
              "etiqueta" => "43"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Kraut JA. Effect of metabolic acidosis on progression of chronic kidney disease. Am J Physiol Renal Physiol 2011;300:F828-9. <a href="http://www.ncbi.nlm.nih.gov/pubmed/21307127" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            43 => array:3 [
              "identificador" => "bib44"
              "etiqueta" => "44"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Wesson DE, Simoni J. Increased tissue acid mediates progressive GFR decline in animals with reduced nephron mass. Kidney Int 2009;75:929-35. <a href="http://www.ncbi.nlm.nih.gov/pubmed/19190678" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            44 => array:3 [
              "identificador" => "bib45"
              "etiqueta" => "45"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Phisitkul S, Hacker C, Simoni J, Tran RM, Wesson DE. Dietary protein causes a decline in the glomerular filtration rate of the remnant kidney mediated by metabolic acidosis and endothelin receptors. Kidney Int 2008;73:192-9. <a href="http://www.ncbi.nlm.nih.gov/pubmed/17978813" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
          ]
        ]
      ]
    ]
  ]
  "idiomaDefecto" => "en"
  "url" => "/20132514/0000003200000006/v0_201502091602/X2013251412002346/v0_201502091603/en/main.assets"
  "Apartado" => array:4 [
    "identificador" => "35445"
    "tipo" => "SECCION"
    "en" => array:2 [
      "titulo" => "Short Reviews"
      "idiomaDefecto" => true
    ]
    "idiomaDefecto" => "en"
  ]
  "PDF" => "https://static.elsevier.es/multimedia/20132514/0000003200000006/v0_201502091602/X2013251412002346/v0_201502091603/en/P1-E544-S3765-A11515-EN.pdf?idApp=UINPBA000064&text.app=https://revistanefrologia.com/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2013251412002346?idApp=UINPBA000064"
]

Article information

ISSN: 20132514
Original language: English

DOI:10.3265/Nefrologia.pre2012.Jul.11515

The statistics are updated each day

Year/Month	Html	Pdf	Total

2024 November	11	10	21
2024 October	67	51	118
2024 September	135	66	201
2024 August	150	89	239
2024 July	118	68	186
2024 June	155	59	214
2024 May	143	57	200
2024 April	125	57	182
2024 March	100	39	139
2024 February	93	41	134
2024 January	74	35	109
2023 December	77	37	114
2023 November	88	45	133
2023 October	79	51	130
2023 September	67	43	110
2023 August	98	33	131
2023 July	87	87	174
2023 June	103	54	157
2023 May	104	60	164
2023 April	67	31	98
2023 March	69	33	102
2023 February	76	25	101
2023 January	75	30	105
2022 December	96	43	139
2022 November	74	38	112
2022 October	96	59	155
2022 September	79	45	124
2022 August	84	62	146
2022 July	74	50	124
2022 June	74	48	122
2022 May	81	48	129
2022 April	133	64	197
2022 March	166	58	224
2022 February	205	69	274
2022 January	145	46	191
2021 December	101	53	154
2021 November	101	53	154
2021 October	115	60	175
2021 September	104	52	156
2021 August	108	37	145
2021 July	136	41	177
2021 June	100	44	144
2021 May	153	50	203
2021 April	664	51	715
2021 March	222	55	277
2021 February	157	28	185
2021 January	138	41	179
2020 December	116	24	140
2020 November	121	38	159
2020 October	74	38	112
2020 September	73	18	91
2020 August	73	20	93
2020 July	92	15	107
2020 June	147	59	206
2020 May	153	25	178
2020 April	122	28	150
2020 March	162	29	191
2020 February	133	30	163
2020 January	132	30	162
2019 December	150	34	184
2019 November	222	34	256
2019 October	215	30	245
2019 September	290	67	357
2019 August	189	50	239
2019 July	178	44	222
2019 June	218	36	254
2019 May	202	35	237
2019 April	309	60	369
2019 March	250	47	297
2019 February	121	26	147
2019 January	136	45	181
2018 December	239	39	278
2018 November	204	25	229
2018 October	182	19	201
2018 September	189	11	200
2018 August	192	17	209
2018 July	110	7	117
2018 June	128	19	147
2018 May	135	17	152
2018 April	120	6	126
2018 March	149	24	173
2018 February	84	9	93
2018 January	102	10	112
2017 December	65	15	80
2017 November	111	13	124
2017 October	86	16	102
2017 September	79	19	98
2017 August	68	30	98
2017 July	73	15	88
2017 June	55	11	66
2017 May	93	18	111
2017 April	82	24	106
2017 March	82	26	108
2017 February	130	10	140
2017 January	52	13	65
2016 December	67	5	72
2016 November	133	7	140
2016 October	130	8	138
2016 September	221	5	226
2016 August	229	2	231
2016 July	188	9	197
2016 June	153	0	153
2016 May	148	0	148
2016 April	136	0	136
2016 March	99	0	99
2016 February	131	0	131
2016 January	121	0	121
2015 December	107	0	107
2015 November	87	0	87
2015 October	105	0	105
2015 September	75	0	75
2015 August	92	0	92
2015 July	93	0	93
2015 June	57	0	57
2015 May	89	0	89
2015 April	7	0	7

Show all

Indexed in:

Follow us:

Statistics

Indexed in:

Follow us:

Statistics

Subscribe to our newsletter